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The objectives of this study were to evaluate the incidence and neurological outcomes of 
out-of-hospital cardiac arrest (OHCA) patients in Finnish intensive care units (ICU). This 
study also investigated the use of therapeutic hypothermia, arterial blood gas pressures and 
different biomarkers association with one-year neurological outcome, mortality or organ 
dysfunction in ICU-treated OHCA patients. 
Materials and methods 
A nationwide, prospective, observational FINNRESUSCI study was conducted in 21 out of 
22 ICUs treating adult cardiac arrest patients in Finland during a one-year study period, 1st 
March 2010 to 28th February 2011. All successfully resuscitated adult patients after OHCA 
who were treated in ICU were included to this study. Blood samples for biomarker 
evaluation were collected from patients at four time points after informed consent, and 
neurological outcomes were determined 12 months after cardiac arrest. Study data were 
collected with Case Report Forms (CRF) and from the Finnish Intensive Care Consortium 
(FICC) database. 
Study I included all FINNRESUSCI study patients and evaluated the incidence and the 
implementation of therapeutic hypothermia (TH) after OHCA in ICU and reported the 
mortality and 12-month neurological outcomes of OHCA patients resuscitated from 
shockable and non-shockable rhythms treated with or without TH. 
In Study II, all arterial blood gas samples obtained from all mechanically ventilated and 
comatose patients during the first 24h from ICU admission were analysed. The mean and 
time-weighted partial pressures of oxygen and carbon dioxide and their associations to 
mortality and neurological outcome were studied. 
In Study III, interleukin-6 (IL-6), high-sensitivity-CRP (hs-CRP) and protein S-100B were 
measured from patients resuscitated from shockable rhythm and their association to the 
duration of ischemia, organ dysfunction and neurological outcome were evaluated. 
In Study IV, high-sensitivity troponin T (hs-TnT) was analysed from a set of patients 
resuscitated from shockable rhythm and with a sample available from ICU admission (<6h). 
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This study evaluated the ability of hs-TnT to predict short- and long-term outcome. 
Main results 
Study I included 548 patients, of whom 311 (56.8%) had shockable (VF/VT) and 237 
(43.2%) non-shockable (PEA or asystole) as an initial rhythm. The population-based 
incidence of OHCA patients in ICU was 13/100,000/year. Out of 504 (92%) unconscious 
patients at ICU admission, TH was induced in 311 patients, 241/281 (85.8%) patients 
resuscitated from VF/VT, and 70/223 (31.4%) patients resuscitated from PEA or asystole. 
Of the 504 unconscious patients 184 (37.2%) had a good neurological outcome (CPC 1-2) 
after 12 months, 147/281 (52.9%) in VF/VT group and 37/223 (17.1%) in PEA or asystole 
group. Good neurologic outcome was achieved 138/241 (58.0%) with shockable rhythms 
and 13/70 (19.4%) with non-shockable rhythms after TH treatment versus 9/40 (22.5%) 
and 24/153 (16.0%) without TH treatment.  
Study II included 409 unconscious and mechanically ventilated patients. The mean carbon 
dioxide (PaCO2) tension during the first 24-hour in ICU was an independent predictor of a 
good outcome with an odds ratio (OR) of 1.054 (95% Confidence interval (CI) 1.006-
1.104), for an increase of 1 mm Hg, but the mean oxygen (PaO2) tension was not OR 1.006 
(95% CI 0.998-1.014). In multivariable regression analysis, the time spent above PaCO2 45 
mmHg was associated with good neurologic outcome OR 1.015 (95% CI 1.002-1.029) for 
each percentage point increase in time, but time spent in different PaO2 categories were not. 
Patients with the highest mean PaCO2 and PaO2 values had better one-year neurologic 
outcome than predicted with an OR of 3.2 (95% CI 1.1-9.2). There was no harmful 
association between hyperoxia and outcome.  
Study III included 186 patients resuscitated from VF/VT. High admission plasma 
concentrations of interleukin-6 (IL-6) and S-100B were associated with time to ROSC and 
poor neurological outcome (p<0.001), whereas hs-CRP was not. Admission IL-6 was also 
associated with extra-cerebral organ dysfunction (p<0.001) with AUC of 0.679. Admission 
IL-6 was an independent predictor of poor neurological outcome after 12 months with an 
OR of 1.006 (95% CI 1.000-1.011) in the multivariable logistic regression analysis. 
Study IV included 155 patients resuscitated from VF/VT. Hs-TnT levels were elevated in 
all of the patients but the levels were higher in patients with poor vs. good neurological 
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outcome 739 (IQR 191-1061) vs. 334 (195-716) ng/l (p=0.028), but there was no statistical 
difference in hospital mortality. Hs-TnT did not improve prognostic information to 
previously known multivariate analysis risk variables. 
Conclusions 
Therapeutic hypothermia or targeted temperature management (TTM) is widely used and 
well implemented in clinical practice in Finnish ICUs. The majority of OHCA patients 
resuscitated from shockable rhythms are treated with TH and withholding TH was due the 
clinical reasons. The majority of OHCA patients with shockable rhythms after TH survive 
with good neurology, while the outcome of patients with non-shockable rhythms is poorer 
despite the TH treatment. Hyperoxia exposure is rare in Finland and a harmful association 
of hyperoxia with outcome was not found. Instead mild hypercapnia combined with mild 
hyperoxia after OHCA might be beneficial during the first 24 hours in ICU. Early 
inflammatory response after OHCA was demonstrated by high levels of admission IL-6, 
which was associated with the duration of ischemia and subsequent extra-cerebral organ 
dysfunction. Admission IL-6 is also an independent predictor of neurological outcome 
along with time to ROSC and age after OHCA-VF/VT. Hs-TnT does not give any 




Out of hospital cardiac arrest (OHCA) is a significant health problem in industrial countries. 
The aetiology and treatment of cardiac arrest has changed, but the overall survival has not 
improved much over the last few decades.  Despite improvements in healthcare and 
intensive care, including therapeutic hypothermia, mortality remains high1.  
 
Established pre-hospital factors affecting survival are initial rhythm, witnessed collapse or 
cardiac arrest, the presence and quality of bystander cardio pulmonary resuscitation (CPR), 
early defibrillation and underlying comorbidities1 Prognosis depends on the circumstances, 
including laypersons’ abilities to recognize cardiac arrests, the organization of dispatch 
centres and emergency medical services (EMS) and the quality of intensive care2. Due to 
these reasons there is a large variation in survival and outcome numbers reported in the 
literature3-5. 
 
Cardiac arrest stops the blood circulation and causes hypoxia of the whole body, and a short 
time Return Of Spontaneous Circulation (ROSC) is essential for any possible recovery. 
Prolonged ischemia causes global tissue and organ injury, but additional damage also occurs 
during CPR and after ROSC in the reperfusion state. Ischemia and reperfusion start unique 
pathological processes in the body.  These processes form what is known as the Post-
Cardiac Arrest Syndrome (PCAS)6,7. The major components of PCAS are brain injury, 
myocardial dysfunction and systemic ischemia/reperfusion response and persistent 
precipitating pathology7,8. The severity of PCAS is not uniform in individual patients and it 
lasts for at least 72 hours9. Potential therapies for PCAS are focused on treatment of these 
separate components and needs intensive care resources to manage in its entirety10.  
 
Brain injury is the most common cause of mortality after cardiac arrest11,12. In PCAS care 
lowering or controlling the patient’s temperature is a major therapeutic intervention to 
prevent or limit brain injury. Therapeutic Hypothermia (TH), where patients are cooled to 
32-34° C for 12-24 hours has been in clinical practice for over a decade since two 
randomized controlled trials13,14 and meta-analysis showed improved outcome in patients 
resuscitated from out-of-hospital Ventricular Fibrillation (VF)15, who remained comatose 
after ROSC and treated with TH. TH has been recommended for standard care for 
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comatose survivors of OHCA with shockable rhythms according to the international 
guidelines ever since16. In the latest RCT, Targeted Temperature Management (TTM) trial, 
950 OHCA patients were randomized into 36 h temperature controls either at 33°C or 
36°C17. The TTM study reported no difference in mortality or neurological outcome 
between the temperature groups. In TTM study fever was prevented in both groups 
compared to previous RCT13, which is the major weakness of this HACA study. The benefit 
of TH or TTM in patients resuscitated from non-shockable initial rhythms has not been 
shown, but despite insufficient evidence, TH was also recommended for all comatose 
OHCA patients chosen to active intensive care according the European Resuscitation 
Council (ERC) guidelines 201018. According to the latest ERC guidelines TTM is 
recommended for all comatose OHCA patients resuscitated from shockable rhythm and 
suggested also for IHCA and OHCA patients resuscitated from non-shockable rhythms 
(weak recommendation, very-low quality evidence)19. Because these recent guidelines allow 
recommended temperature control between 32°C to 36°C, the term temperature control or 
targeted temperature control is preferred and has replaced the term TH in the latest 
literature. 
 
Individual components of PCAS are potentially treatable and may each have some influence 
on survival1,8,10. Therapeutic strategies like ventilation, circulatory and haemodynamic 
support, glucose control, sedation, management of coronary syndrome and treatment of 
other causes of CA are focused on these components of PCAS. However, the optimal target 
levels of some treatments and therapies are still unknown8.  
 
Cardiac arrest patients, who are common in ICUs, use limited intensive care resources and 
cause substantial costs to the health care system. Therefore, it is important to gain 
knowledge on therapeutic strategies used in ICUs and their effects on outcomes. It would 
be also very useful to get early information on subsequent clinical problems to optimize 
treatments adequately. Another very important aspect of post resuscitation care is early and 
accurate outcome prediction. If available, it would help the clinicians to make decisions in 
patient selection for intensive care or the withdrawal of intensive care when outcomes are 
predicted to be undesirable. 
 
The aims of this study were to evaluate the incidence and outcome of OHCA patients in 
ICUs in Finland. In addition, the study focused on the use of therapeutic hypothermia, post 




2 REVIEW OF THE LITERATURE 
2.1 Out of hospital cardiac arrest 
Cardiac arrest, a sudden loss of heart function, stops the circulation immediately and causes 
unconsciousness in a few seconds. Ischemic Heart Disease (IHD) is the leading cause of 
cardiac arrest20,21 and cardiac arrest may be the first symptom of IHD. Cardiac arrest and 
loss of blood flow lead to general ischemia and cerebral injury6, which is the leading cause 
of death after cardiac arrest6-8,11,12. The purpose of pre-hospital cardiopulmonary 
resuscitation (CPR) is to minimize the time of no blood flow with chest compressions, take 
care of ventilation and reverse unexpected cardiac arrest. High quality pre-hospital EMS 
also guarantees sufficient circulation and ventilation of successfully resuscitated patients 
during transportation to hospitals. The purpose of hospital and ICU care is to minimize the 




Sudden cardiac arrest is one of the leading causes of death in Europe and the USA. Cardiac 
arrest occurs in 0.5-1.0 per 1000 inhabitants a year, depending on how cardiac arrest is 
defined, affecting approximately 500 000 individuals in Europe and 200 000 in the USA 
each year1,4,22.  Variations between incidences is reported to be between 37 and 121 per 100 
000 inhabitants/year due the regional variations in Emergency Medical Service (EMS) 
systems between countries3-5,23-25. OHCA patients are treated 100% by EMS services in 
Finland5,26 and approximately 60% in USA27. The incidence of attempted resuscitation 
varies between countries depending on EMS systems and national legal aspects4. The overall 
incidence of OHCA with resuscitation attempted by EMS is reported to be 51/100 000 
inhabitants/year in Finland5 and in Helsinki, the largest city of Finland 80/100 00026. 
OHCA patients have VF as an initial rhythm in 25-50% cases5,25,26,28,29 but the incidence of 
OHCA-VF has been decreasing over the last few years28,30,31. ROSC and survival to hospital 
admission is reported to be around 30-35% of all attempted resuscitations in 
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Scandinavia5,26,32, but only selected patients are treated in ICUs26,32. The incidence of cardiac 
arrest patients treated in ICU was 15/100 000/ inhabitants/year between 2004-2005 in 
Finland33. 
Despite the improvements in specific treatments and knowledge, the overall survival rate 
has been stable and has remained low over the last 30 years1,34. The average survival to 
hospital discharge is reported to be 7.6% in Europe and the USA1,4,34,35. Survival rate is still 
highly dependent on pre-hospital key factors (witnessed CA, bystander CPR, initial rhythm, 
ROSC) despite the improved treatment in ICUs1,36.  
 
2.1.2 Prehospital factors associated with survival 
There are several factors affecting survival from OHCA, including the action of bystanders 
in recognizing the cardiac arrest, making an emergency call to a dispatching centre (112) and 
starting basic life support (BLS), high-quality post resuscitation care in an ICU and 
rehabilitation after hospital care. Each of these factors is important separately, but the last 
years have been shown the importance of the whole chain of treatment in the resuscitation 
guidelines, the so-called chain of survival18. 
 
 
Figure 1. The Chain of survival. Adapted from the European Resuscitation Council 





Short time intervals are the most important factors in the treatment of cardiac arrest. Early 
bystander CPR has a beneficial effect on survival rate and each minute of delay in the 
initiation of CPR decreases the chance of survival 3% until CPR starts37. Immediate CPR 
can double or even triple the survival rate with OHCA-VF patients38,39. Early defibrillation 
is beneficial with VF patients, with each minute of delay in defibrillation reducing the 
probability of survival by 10-12%36,38. 
The presence of a shockable rhythm (VF/VT) is a significant and independent predictor 
of survival and discharge from hospital after successful resuscitation from cardiac arrest1,40. 
VF or VT usually represents the cardiac origin of cardiac arrest, while asystole and PEA as 
initial rhythms more often represent a non-cardiac origin or reflect a long delay from cardiac 
arrest to the time of initial rhythm recognition. VF patients have several times better 
chances to survive than patients resuscitated from non-shockable rhythms15,24,41. Pooled OR 
for survival to hospital discharge of OHCA-VF patients compared to patients found with 
non-shockable rhythms ranged from 2.91 (95% CI 1.10-7.66) to 20.62 (95% CI 12.61-33.72) 
depending on the baseline survival of the studies1.  
Overall survival rates vary in studies around the world, but the highest survival rates have 
been reported in the studies with the highest proportion of patients found with VF4.  
When evaluating key predictors of OHCA patients in meta-analyses, patients who are 
found with shockable initial rhythm (VF/VT) and received CPR from a bystander or an 
EMS provider, have significantly better chances to survive than those who do not.  The 
better survival of VF or VT patients is associated with locations where a defibrillator is 
available at public sites42. Of VF/VT patients approximately 1 of every 4 to 7 patients 
survive to hospital discharge, compared to patients found in asystole, of whom only 1 of 
every 21 to 500 patients survive1.  
There is a great variation in the published survival rates between different countries4 and 
also regional variations between EMS systems, cities and rural areas3,5,43. 
 
2.2 Post cardiac arrest syndrome 
Whole body ischemia, caused by cardiac arrest, and reperfusion caused by return of 
spontaneous circulation (ROSC) after successful CPR creates a specific pathophysiological 
state. This phenomenon was first described in the early 1970s and named post resuscitation 
disease44, later called post-cardiac arrest syndrome (PCAS)8. The pathological process 
actually begins at the time of collapse and continues during CPR and in the reperfusion 
phase45,46 for several hours after ROSC, even though the actual resuscitation has ended. 
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PCAS can be divided into four main components by individual organ systems; i) post-
cardiac arrest brain injury, ii) post-cardiac arrest myocardial dysfunction, iii) 
ischemia/reperfusion syndrome and iv) persistent precipitating pathology. The severity of 
disorders in these organ systems is not uniform, but it varies in individual patients based on 
the patient´s comorbidities and state of health, the cause of cardiac arrest and the time of 
ischemia. PCAS may not occur and the patients regain consciousness, if ROSC is achieved 
rapidly after cardiac arrest. 
 
 
Figure 2. Phases and treatment goals of Post Cardiac Arrest Syndrome (PCAS). 






2.2.1 Post cardiac arrest brain injury 
Brain injury is the most common cause of death after OHCA11,12. Brain tissue is more 
vulnerable to ischemia compared to other organs and ischemic injuries occur as early as a 
few minutes of ischemia. After cardiac arrest reperfusion is often hyperdynamic and 
cerebral perfusion pressure (CPP) is often elevated because of impaired cerebral 
autoregulation47,48. Despite adequate cerebral perfusion pressure (CPP), the failure of the 
cerebral microcirculatory may lead to ischemia and local infarcts in some brain areas in 
animal models49,50. Systemic blood pressure correlates with CPP, and mean arterial blood 
pressure influences neurologic outcome after cardiac arrest51. Hypoxemia and brain oedema 
also influences oxygen delivery to the brain and possible brain injury especially after CA. 
The partial pressures of arterial blood gases (ABG) have an effect on blood circulation in 
brain tissue due the vasoconstriction or vasodilation of blood vessels52,53. Hypocapnia 
reduces intracerebral pressure (ICP) and increases cerebral perfusion pressure but 
vasoconstriction in blood vessels may cause harmful ischemia in the brain tissue52. On the 
other hand, hyperoxia causes oxidative stress and is harmful for neurones after ischemic 
insult in animal models54-56. The effects of the partial pressures of arterial blood gases is a 
complex question57 but ABG tensions may have an influence on the severity of brain 
damage. 
2.2.2 Post cardiac arrest myocardial dysfunction 
Haemodynamic instability, variation of heart rate and blood pressure, is very commonly 
seen after ROSC, but it often stabilizes after the circulating catecholamine concentrations 
decrease58. Instant myocardial dysfunction, established by the low ejection fraction and high 
end diastolic pressure of the left ventricle can be detected right after ROSC by appropriate 
monitoring59. This dysfunction is not only related to ischemia, but also to reperfusion 
leading to the myocardial stunning phenomenon manifested by hypotension, tachycardia 
and low cardiac output60-62. Because this phenomenon is usually transient and major 
recovery occurs under 72 hours60,62,63, myocardial dysfunction is partly responsible for 
deaths in the first three days, while brain injury is responsible for the later deaths11,12. 
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2.2.3 Systemic ischemia/reperfusion response 
Cardiac arrest and debt of oxygen causes the most severe shock state in the tissues and leads 
to activation of the endothelium64. Low oxygen level itself is predictive for organ failure and 
increasing mortality65 and combined with the activation of immunological and coagulation 
systems leads to a condition similar to sepsis66. Intravascular volume depletion, 
vasodilatation, release of various cytokines and endotoxins, endothelial injury leads to 
increasing risk of multiple organ failure and infections67-70  
Therapeutic strategies after CA in ICU are focused mainly on optimizing the clinical 
manifestations of the immune response, optimizing haemodynamics and organ perfusion. 
The primary tools for this are intravenous fluids, inotropes, vasopressors and blood 
transfusions. Early Goal Directed Therapy (EGDT), where the balance between oxygen 
demand and consumption is in focus, has clinical benefits in patients with sepsis, such as 
identification of patients at high risk to CA71.  EGDT has been shown to reduce post-
operative complications, the duration of hospital stay and mortality after major surgery72 but 
it does not have the same effects for sepsis73. The optimal goals for haemodynamic 
parameters have not been studied in randomized trials for CA patients and are still unclear, 
but since PCAS have features common to sepsis, the principles of EGDT might be 
beneficial in the care of CA patients7. The magnitude of PCAS described by changes in 
cytokine, endotoxin and systemic inflammation marker levels has been reported to associate 
with the outcome70,74  
 
2.2.4 Persistent precipitating pathology 
Coronary artery disease is a very common pathology among OHCA patients21 and 
myocardial infarction is the leading cause of sudden cardiac death75. Acute coronary 
syndrome (ACS) is the most common cause of OHCA. A high incidence (48%) of acute 
coronary occlusion after OHCA was reported already in 199776 and the prevalence of 
significant coronary artery disease ranged from 59% to 71%  for OHCA patients in a recent 
meta-analysis77. Probable ACS can be identified by clinical symptoms or measurements. 
Chest pain before cardiac arrest, ST-segment elevations in ECGs are the classic 
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manifestations of ACS, but their predictive value is poor among CA patients76. The majority 
of patients with ST-segment elevation in their ECGs after ROSC have acute coronary 
lesions78. The absence of ST-segment elevation does not exclude ACS as a cause of cardiac 
arrest in OHCA patients79-82. In many observational studies early cardiac interventions, 
angiography and percutaneous coronary intervention (PCI), increased survival rates and 
associated with better neurological outcomes, especially in patients with ST-segment 
elevation79,81, but there are no randomized studies which would validate this benefit.  
Because the success and feasibility of early angiography and PCI is also well documented83-
86, the latest ERC guidelines recommend early coronary intervention for all patients with 
ST-segment elevation after OHCA. Coronary angiography should be also considered for all 
patients with a probable cardiac cause for OHCA87  
Other possible diagnoses for CA are pulmonary embolism, sepsis, metabolic disorders, 
hypoxemia, hypothermia, cardiac tamponade, pulmonary diseases, haemorrhage, 
intoxications and electrolytic disturbances which are more common among IHCA patients 
and patients with non-shockable initial rhythm88. These causes of cardiac arrest should be 
diagnosed and treated early, if possible during the CPR89. 
 
2.3 Intensive care 
Post resuscitation care starts at the venue where ROSC is achieved, but usually the patient is 
transferred to the next care level area for monitoring, diagnosis and treatment, depending 
on local hospital circumstances and the patient’s clinical state. Depending on the cause of 
arrest, time delays to CPR and defibrillation and duration of CPR, some OHCA patients do 
regain consciousness rapidly after successful ROSC1,37,90. Despite the possible return of 
consciousness, many of these patients still require treatment to optimize ventilation91,92, 
haemodynamics7, glucose control93 and multiple organ support. The purpose of intensive 
care after cardiac arrest is to focus on treating disorders of the PCAS components and 
adjust the treatment balance between all the injured organ systems. PCAS is a very complex 
state and monitoring and treatments of these patients is possible usually only in ICU 
circumstances, but according to growing knowledge, all the key components of PCAS are 
individually potentially treatable. Standardized treatment and local protocols do have 
significant influence on the overall outcome and especially on the most important outcome 
parameter, neurological outcome83,94-96. 
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2.3.1 Temperature control after cardiac arrest 
Hyperthermia is very common after CA97 and there is a clear association between 
hyperthermia and poor neurological outcome97-100 Hyperthermia after mild therapeutic 
hypothermia (32°C-34°C), so called rebound hyperthermia, is associated to unfavourable 
neurological outcome101,102. Since 2003 mild TH, where patients are cooled to 32°C-34°C 
for 12-24 hours has been recommended for OHCA patients resuscitated from VF/VT who 
are selected for intensive care16. According to the 2009-2010 international guidelines TH 
recommendation extended also for non-VF-OHCA and in-hospital cardiac arrest (IHCA) 
patients selected for intensive care18,103. The term targeted temperature management (TTM), 
where temperature is maintained between 32°C-36°C, was born after publication of a large 
randomized trial 2013 by Nielsen and colleagues 17. In that TTM trial, fever was prevented 
in all patients and it reported equal mortality and neurological outcome with patients treated 
at both temperatures, i.e., 33°C and 36°C17. Today the international consensus is to use 
TTM or temperature control instead of the term TH in the care of CA patients. According 
to a recent ILCOR consensus statement and the latest ERC guidelines 2015 TTM (32°C-
36°C) for at least 24 hours is strongly recommended for all comatose OHCA VF patients 
and weakly for other CA patients19,104.  
2.3.1.1 Hypothermia  
 
Therapeutic hypothermia is neuroprotective and the only well documented therapy for 
preventing brain damage after ischemic insult or lack of blood flow105-107. The exact 
mechanism is unclear, but hypothermia is thought to have several beneficial effects in 
reducing brain injury. General cellular metabolism slows significantly for every one degree 
drop in body temperature108. Accordingly hypothermia is shown to reduce oxygen 
consumption in brain tissue in animal models109,110, but also the body´s need for oxygen is 
thought to be reduced111. Hypothermia has been shown to affect many chemical and 
physical mechanisms at the mitochondrial level, on apoptosis, cell membranes stability and 
production of free radicals, cytokines and other inflammatory mediators111. Evidence of 
these models comes mainly from animal studies. Cells can recover from acute ischemia, but 
it can still lead to the programmed cell death pathway, apoptosis, which is determined by the 
effects of mitochondrial dysfunction on energy metabolism112. Hypothermia can prevent 
cells taking to apoptosis pathway113 and prevent mitochondrial dysfunction114. High levels 
of excitatory neurotransmitter, glutamate and free oxygen radicals, are toxic to neuronal 
cells. Hypothermia reduces the release of glutamate to the extracellular space115 and 
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decreases the amounts of free radicals that are produced during ischemia116,117 
Ischemia induces the raise of inflammatory mediators, this begins early after reperfusion and 
levels remain elevated for up to 5 days. Therapeutic hypothermia reduces inflammatory 
reactions and the release of inflammatory cytokines after ischemia and during 
reperfusion118,119. It also decreases the production of nitric oxide, which plays an important 
role in the development of ischemic brain damage115. According to animal studies the size 
of neuronal damage can be decreased by inhibiting some or all of these mechanisms115. 
2.3.1.2 Clinical evidence for hypothermia and temperature control 
Several animal studies from the 1990s have shown that hypothermia (30°-34° C) 
significantly improved the neurological outcome of dogs after cardiac arrest120-124. These 
animal studies led to two human clinical trials published in 200213,14, which both reported 
significant improvement of neurological outcome with therapeutic hypothermia treatment 
compared to patients treated without TH after OHCA. Soon after publication of these 
studies mild therapeutic hypothermia (32°-34°) for 12 to 24 hours was recommended for 
clinical practice16 and later included in international guidelines125. TH implemented was 
relatively soon to post resuscitation care, and there are several before and after studies on 
cardiac arrest outcome, which all support the benefit of TH, especially in the VF 
group32,83,126,127. The benefit of TH has been shown also in a systematic review128 and 
benefit is also reported for CA patients with presumed cardiac origin in meta-analysis 
200515.  
Despite the shown benefit of TH for VF patients, the benefit in patients with non-
shockable initial rhythm is not visible in these historical studies. Studies of patients 
resuscitated from non-shockable rhythms reported conflicting results from possible benefit 
of TH83,129,130. A registry study of 1145 patients treated with TH concluded there was a 
positive association between TH and neurological outcome in VF patients with an OR of 
1.9 (95% CI 1.18-3.06) but no benefit in patients in PEA/asystole, OR 0.71 (95% 0.37-
1.36)131. The clear evidence of benefit is still missing despite the large registry studies and 
meta-analysis, with partly contradictory results132-134 TH has been also studied in large 
registry study with in-hospital cardiac arrest (IHCA) patients, but no difference was found 
in their survival, OR 0.9 (95% CI 0.65-1.23)135. Summary of these studies are presented in 





















































TH or TTM is generally safe but side effects also occur17,136 and most of the physiological 
side effects are treatable in ICU circumstances137. The most common and generally known 
physiological responses to hypothermia are cardiac arrhythmias, usually bradycardia136,138, 
increased diuresis and electrolyte disturbances17,136,137 and hyperglycaemia14,136 which is 
strongly associated to poor neurological outcome93,139. Mild induced hypothermia has 
effects on the coagulation system and it may increases bleeding140, but it seems not have 
clinical relevance13,17,33,83. The immune system is also impaired by TH, which increases the 
infection rate137,141,142. TH is also associated with increased incidence of pneumonia143,144. 
There is no clear evidence of a negative impact of infections on the outcome even though 
the early use of antibiotics may be beneficial 145. Bradycardia during hypothermia is 
associated with favourable neurological outcome146,147. 
 
TTM treatment can be divided into three phases; induction, maintenance and rewarming137. 
There are several internal and external techniques used in induction and maintenance of 
hypothermia; ice packs, ice-cold saline, cooling blankets or intravascular devices, which all 
have benefits and disadvantages. Prior recommendations suggested rapid cooling after 
ROSC16 and for mainly this reason ice-cold saline in large volume, usually 20-30ml/kg -1 
was widely used in prehospital settings, including in Finland5. The use of ice-cold 
intravenous fluids have been studied in RCTs 148-151, but no positive impact on mortality or 
neurological outcome was found for these or other prehospital cooling 152 studies (RR, 0.98; 
95% CI, 0.92-1.04). According to present knowledge, during the maintenance phase 
avoiding temperature variation with adequate monitoring is preferred using external or 
internal device compared to other techniques. On the other hand, there is no evidence that 
any cooling technique is superior to the others and would increase survival, but internal 
devices are better for precise temperature control compared to external techniques153,154. 
During the rewarming phase electrolyte concentrations, metabolic rate and intravascular 
volume can change rapidly. Avoiding possible rebound hyperthermia, which is shown to be 
harmful 101,155 a slow rate of rewarming of 0.25-0.5°C per hour is recommended 19,129. 
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2.3.2 Ventilation and blood gases 
All patients who remained comatose after successful ROSC need ventilatory support, 
usually tracheal intubation and mechanical controlled ventilation. The ventilation strategy 
used influences the patient’s arterial blood concentrations of oxygen and carbon dioxide 
(CO2).  Blood gas concentrations may affect the brain and other organs’ blood perfusion, 
oxygen delivery and outcome. Nearly all comatose patients after CA in ICUs are 
mechanically ventilated, but the treatment goals for safe and optimal levels for oxygen and 
carbon dioxide are unknown156.   
2.3.2.1 Oxygen 
Hyperoxia is harmful for neurones in animal models 56, but human studies of this issue is 
heterogeneous (Table 2). One small randomized human study reported an association 
between the administration of 100% oxygen and elevated levels of NSE comparing to 30% 
oxygen to CA patients after ROSC157.  According to one registry study with over 6000 
patients hyperoxia during the first 24 hours after CA was associated with poor neurological 
outcome compared to normoxemia and hypoxemia158. In a further analysis a dose 
dependent association with a poor outcome was reported159. In contrast, according to 
another observational study on over 12 000 patients, hyperoxia was not associated with 
increased mortality160. A recent meta-analysis shows significant heterogeneity across studies 
about this association161. Hyperoxia might be harmful, but at the same time all interventions 
reducing oxygen exposure also increases the risk for hypoxia, which is also associated to 
increased mortality158,160. The precise titration of oxygen is possible after a patient’s arrival at 
hospital using ventilator and ABG values, but there is clear feasibility problem in prehospital 
setting, when only oxygen saturation by pulse oximetry (SpO2) is used as an oxygenation 
target162. Out-of-hospital location of cardiac arrest and long time delay in ICU admission are 




































































2.3.2.2 Carbon dioxide 
Despite the autoregulation of cerebral blood flow is dysfunctional after CA48, reactivity to 
changes in partial pressure of carbon dioxide (CO2) seems to be preserved and CO2 tension 
has an influence on blood flow in brain tissue164,165. In animal models mild hypercapnia 
improved cerebral perfusion and protected brain cells after ischemic insult166 and 
hypocapnia is associated with increased neuronal injury167. The same results are seen also in 
human patients after traumatic brain injury52,168-170. Carbon dioxide has anticonvulsant171, 
anti-inflammatory and anti-oxidant properties172, which may be beneficial for preventing 
brain damage. Hypocapnia after CA induced by hyperventilation has been shown to cause 
cerebral ischemia also in humans173,174. The effects of carbon dioxide on cardiac arrest 
patients have studied in observational registry studies91,92. Both these studies reported an 
association between hypocapnia and poor neurological outcome, but another study found 
an association between hypercarbia and a higher rate of discharge from hospital with an OR 
of 1.16 (95% CI 1.03-1.32), which was considered a surrogate marker of favourable 
neurological outcome92. CO2 tension can be controlled in almost all the patients after CA, 
because of mechanical ventilation175. Lowering patients’ temperatures in ICU during TH or 
TTM decreases their metabolism and production of CO2. This may lead to hypocapnia176, 
which is preventable by adjusting minute ventilation.  
 
2.4 Biomarkers after cardiac arrest 
Ischemia and cell damage in different tissues leads to the release of several biomarkers and a 
wide range of these different biomarkers have been studied in patients with CA.  The main 
goal has been to find a prognostic tool for identifying patients with no chance of recovery 
or to plan specific treatments during ICU care. Despite several studies no single biomarker 
has been shown to be a reliable predictor of relevant outcome177,178 
Cardiac arrest and successful ROSC leads to similar systemic inflammatory responses like 
those seen in patients with sepsis66, called PCAS7. The severity of PCAS is variable in 
individual patients, based on the severity of the ischaemic insult and the patient´s state of 
health before CA. Ischemia and following activation of inflammatory response increases the 
risk of multiple organ dysfunction67,69 and the development of organ dysfunction after CA 
will worsen the patient´s outcome70. Various levels of inflammatory biomarkers have been 
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associated with tissue hypoxia, organ dysfunction and mortality in sepsis patients and these 
support the need for early haemodynamic optimization and may help clinicians to tailor 
other treatments strategies7,179. Several inflammatory biomarkers have been studied in 
critical care patients180, but interleukins, procalcitonin, TNFα and CRP are the most studied 
biomarkers in cardiac arrest settings177.  
Hypoxic-ischemic brain injury is very common after CA and the majority of patients die 
from brain injury11 also after implementation of TH or TTM12,17. All neurological biomarker 
studies have been trying to find a clinical tool to identify brain injury and to predict poor 
neurological outcomes. From these neurological biomarkers, neuron specific enolase (NSE) 
181-186 and protein S-100B181,185,187,188 are the most studied biomarkers. 
Post cardiac arrest syndrome, which includes myocardial dysfunction and stunning 
affects the majority of OCHA patients7 and severity of PCAS is a contributing factor to 
mortality12. Coronary artery disease, acute coronary syndrome (ACS) including myocardial 
infarction is the most common cause for cardiac arrest20,21. The cardiac aetiology of CA is 
manifested by VF and pulseless VT as an initial rhythm, but acute coronary artery lesion was 
also present in 59% to 71% of OHCA patients without a presumed cardiac aetiology77. 
Observational studies have shown that early invasive cardiac interventions, including PCI, 
are feasible85,86 and it is probable that invasive management is beneficial in OHCA patients, 
especially with classic AMI manifestations79,85. The cardiac biomarkers, (TnT, TnI) have 
been studied to establish cardiac risk factors and possible prognostic values in OHCA 
patients177. 
2.4.1 Inflammatory biomarkers- IL6 and CRP 
 
Interleukin-6 (IL-6) is an inflammatory cytokine, which is one of the main stimulators for 
the production of other acute phase proteins, which are clinically measurable, like C-reactive 
protein (CRP)189. Systemic levels of IL-6 correlates with organ dysfunction and outcome in 
sepsis patients in experimental190 and in clinical191 studies. IL-6 and CRP have been studied 
in CA settings, which reporting increased levels of CRP after CA, but no correlation has 
been shown in infectious complications to time of anoxia or outcome192-194. Respectively in 
one small study IL-6 in the cerebrospinal fluid correlated with neurological outcome after 
CA195 and plasma concentrations of both IL-6 and high sensitivity-CRP (hs-CRP) correlated 
with poor outcome in another study196. Hypothermia has effects on the release of 
inflammatory biomarkers, but TH did not affect the IL-6 response, thus the release of CRP 
was suppressed by TH142. 
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2.4.2 Neurological biomarkers- S-100B 
S-100B is a brain protein originating from the astroglial and Schwann cells, which is released 
from brain cells after ischemia. S-100B correlated with neurological status at admission, 
functional outcome and stroke volume in patients with ischemic stroke197, but the evidence 
with cardiac arrest patients is not well documented. The first studies of S-100B reporting 
higher concentrations at 24 h in patients with poor outcome compared to good outcome 
(0.78 vs. 0.19 mg/l) almost 20 years ago198.  In addition, the cut off value for persistent 
coma was reported to 0.7 mg/l with high positive predictive value (95%) and high 
specificity (96%). Since then the majority of the studies have reported a high specificity, but 
low sensitivity for S-100B as an outcome predictor199-203. S-100B levels are raised after 
cardiac arrest and it correlates with neurological outcome, but there is too great variability in 
the cut-off values to predict poor neurological outcome177,178.  
S-100B’s ability to predict long-term neurological outcome has been studied in prospective 
settings with OHCA patients. S100B levels over 0.29 microg/l at 24-48 h correlated to 
moderate or severe neurological dysfunction and increased levels predicted hospital 
mortality with 100% specificity for a cut off value 1.2 microg/l199. Results from studies 
comparing the predictive values of different neurological biomarkers are also variable, some 
of these studies report a superior value for S-100B in comparison with other 
biomarkers188,198,204, whereas some studies report similar or better predictive values for 
NSE181,185. These discrepancies are probably related to variations in study populations, initial 
rhythms, witnessed or unwitnessed CA and whether hypothermia was used. Nevertheless 
according to the current literature S-100B or NSE are not sufficiently predictive for 
neurologic outcome with 100% accuracy, especially with CA patients treated with TH205. 
There is limited evidence that increasing levels of NSE at 48-72 after CA would predict 
poor neurological outcome183,185,206. This result is supported by a recent TTM substudy 




2.4.3 Cardiac troponins 
Cardiac troponins T and I are part of the contractile apparatus of cardiomyocytes, which 
leak into the circulation when cardiomyocyte injury occurs208. The measurement of 
troponins is used for diagnostic purposes in acute myocardial infarction209-211. New high-
 31 
sensitivity Troponin-T (Hs-TnT) measurement detects significantly lower concentrations of 
troponin than previous assays212.  The clinical benefit of Hs-TnT assay has been reported in 
patients with stable coronary artery disease213 and also reported to be superior to older 
troponin assays for prognostic assessment in cardiovascular diseases, including AMI214-216. 
CPR and defibrillation causes myocardial injury and the duration of CPR plus the number 
of defibrillation shocks increases troponin levels in OHCA patients217-219. Probably due to 
this, troponin studies so far have reported only insufficient accuracy for diagnosing acute 
coronary occlusion after CA220-222. Myocardial dysfunction leads to impaired blood 
circulation and is at least partly responsible for deaths in the first days after CA12. The 
prognostic values of troponins after CA in homogenous study populations have not so far 
been studied.  
 
 
2.5 Outcome  
2.5.1 Mortality 
Mortality is a robust measurement of outcome and the only reported outcome variable 
especially in historical studies. The Utstein guidelines for OHCA223 have since 1991 
recommended the reporting of hospital mortality and one year mortality for all OHCA 
studies. Mortality is reported to be high among CA patients and it is highly dependent on 
the study population and EMS system. Published rates of survival to hospital discharge 
range from 0.3% in Detroit USA224 to 20.4% in Slovenia225. Median survival is reported to 
be 6.4% for cities43.  Despite the high mortality, according to data from large registries, the 
majority of patients who survive to hospital discharge, are reported to be in good 
neurological condition, (85% -92%), depending on the initial rhythm136.  
2.5.2 Neurological outcome 
Neurological outcome according to CPC classification (Table 3), CPC 1-2 representing 
good and CPC 3-5 representing poor outcome, is recommended and clinically relevant 
outcome measurement in OHCA studies.223 According to the Utstein template for 
resuscitation registries and studies, CPC at hospital discharge is classified as core data for 
good quality studies and comparisons of outcomes between studies226, but long-term 
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neurological outcome is clinically more relevant. Neurological status is mainly observed at 
hospital discharge and is a surrogate measure of long-term survival and informative when 
evaluating resuscitation research.227 Most surviving patients are classified as having good 
neurological status at hospital discharge, but emotional and cognitive problems are 
common.227-229 
 
Table 3. Neurological outcome after OHCA. The Glasgow-Pittsburgh Cerebral 
Performance Categories (CPC)223. 
 
OHCA, Out of Hospital Cardiac Arrest 
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2.5.3 Factors associated with outcome variation 
 
Good Survival rate is highly dependent on pre-hospital key predictors of survival (witnessed 
CA, bystander CPR, initial rhythm, ROSC) despite the quality or treatments in ICU care1. 
Reported survival vary between countries and there is also regional variation among 
hospitals treating CA patients230-233. Regional variation in CA patients and outcome is also 
reported in Finland5. There is some evidence that in larger hospitals that take care of more 
than 50 CA patients per year, survival rate would be higher than in hospitals admitting less 
than 20 patients per year233. In one study this difference between hospital size and survival 
disappeared when the results were adjusted for patient related factors234. Some studies also 
report an association between survival and transport and treatment in so called cardiac 
arrest centres234-238. There is no clear definition of a cardiac arrest centre and there is 
inconsistency in the services needed for the cardiac arrest centre status. General consensus 
is that facilities provide TTM and cardiac catheterisation laboratory accessible 24/7. 
Implementation of post resuscitation protocol, including post resuscitation care with TH 
and invasive coronary interventions, has shown to improve survival in historic control 
studies83,95,126,239. Improved survival has been reported in large hospitals with cardiac 
catheter facilities compared with smaller hospitals without these facilities233,235 and a 
combination of early coronary intervention and TH is also associated with favourable 
outcome240. 
 
2.5.4 Outcome prediction  
 
The Sequential Organ Failure Assessment score (SOFA)241 and Acute Physiology and 
Chronic Health Evaluation II (APACHE II) 242 are widely used disease severity scorings in 
ICU care. The SOFA score describes the severity of organ failures (Table 4) and predicts 
mortality in medical or surgical ICU patients243. The SOFA score is not available at 
admission time and not useful or for CA patients, because a SOFA score includes points for 
level of consciousness, which gives maximal points for comatose CA patients. Some studies 
have used SOFA subscores244 and extra-cerebral SOFA scores, excluding the neurological 
component of SOFA for outcome and organ failure prediction70. Extra cerebral SOFA has 
been associated with hospital mortality mainly due haemodynamic instability70. APACHE II 
has been studied in CA patients, but it seems to be a poor predictor of outcome for OHCA 
patients245,246.  
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* Not included in extra cerebral SOFA scores 
 
Prognostic scoring systems, using data available at hospital admission for early outcome 
prediction have been also developed for OHCA patients247,248. These scoring systems use 
initial rhythm, age, time from collapse to BLS (no-flow time), time from BLS to ROSC 
(low-flow time), location of cardiac arrest, epinephrine dose, arterial pH, serum creatinine 
and lactate values for scoring calculations. The OHCA-score was developed using data from 
130 patients mainly treated without temperature control but validated with 210 patients 
mainly treated with TH. The OHCA-score predicted poor neurological outcome with good 
accuracy (AUC 0.88), but later clinical studies could not repeat the results183,245. The OHCA-
score has also been criticized for too low specificity to clinical use249. To ensure that all 
patients with potential favourable outcomes are treated, specificity should be close to 1 with 
a tight 95% CI. The recently published CAHP (Cardiac Arrest Hospital Prognosis)-score 
predicted poor outcome with good accuracy (AUC 0.93) and a CAHP-score over 200 points 
predicted poor neurological outcome with very high specificity (96-100%) for poor 
neurological outcome248.   
 
Brain injury is the leading cause of death in CA patients and prognosis is significantly related 
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to the severity of brain injury, but also a pessimistic prognosis leads to the withdrawal of 
treatment and death12,250. An ideal prognostication tool should predict poor outcome with 
100% specificity and its false positive rate should be zero. But since such a prognostic tool 
for poor outcome is unavailable, multimodal prognostications, including clinical signs, 
biomarkers, imagination and neurological tests are recommended for all patients to predict 
poor outcome and possible withdrawal of intensive care178. The latest ERC guidelines 
adapted the prognostication strategy algorithm from this advisory statement178 and 
recommends an algorithm for all comatose CA patients after 72 hours from ROSC19.  
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3 AIMS OF THE STUDY 
The main aims of this study were:  
 
1. To evaluate the incidence of adult OHCA-patients treated in Finnish ICUs (I) 
 
2.  To evaluate the use of therapeutic hypothermia and its possible associations 
with one-year neurological outcome after OHCA (I) 
3. To study the association between partial pressures of oxygen and carbon 
dioxide during the first 24 hours of intensive care and one-year neurological 
outcome after OHCA (II) 
 
4. To evaluate the ability of biomarkers IL-6, hs-CRP and S-100B to predict 
subsequent severe organ dysfunction and one-year neurological outcome after 
OHCA from shockable rhythm (III) 
5.      To evaluate the ability of hs-TnT to predict mortality and one-year 
neurological outcome in OHCA patients with shockable rhythm (IV) 
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4 PATIENTS AND METHODS 
4.1 Patients 
This study included 548 adult patients resuscitated after out-of-hospital cardiac arrest and 
treated in 21 ICUs. All the patients were from the prospective, nationwide, observational 
FINNRESUSCI study, which included all adult patients treated in ICU after OHCA in 
Finland during the one-year study period, 1st March 2010 to 28th February 2011. In total 21 
out of 22 ICUs treating adult cardiac arrest patients participated in this study. 
Approximately 98% of the whole Finnish adult population (4 290 980 at 31/12/2010) live 
in the referral areas of these ICUs. The study protocol was approved by the Ethics 
Committee of the Department of Surgery in Helsinki University Hospital and by the Ethics 
committee of each participating hospital when necessary. Written informed consent was 
given by the patient or next of kin for all patients for blood samples and for one-year 
neurological outcome. 
The inclusion criteria for the FINNRESUSCI study were: 
 
1. Out-of-hospital cardiac arrest 
2. Successful resuscitation 
3. Age over 18 years 
4. Post-resuscitation care in ICU 
 
Study I included all FINNRESUSCI study patients (n=548). Study II included a total of 
409 patients. All these patients despite the initial rhythm were mechanically ventilated, 
comatose at ICU admission, ABG measured and recorded in the database and outcome data 
available 12 months after cardiac arrest. Study III included 186 patients resuscitated from 
shockable initial rhythm (VF/VT) and with blood samples available from the first 24 hours 
from ICU admission. Study IV included 155 patients resuscitated from VF/VT and with 
blood samples available from the first 6 hours from ICU admission. Table 5 presents the 
number of patients and inclusion criteria for each study and a flowchart of the study 
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patients is presented in Figure 3. 
 
Table 5. Numbers of patients in Studies I-IV 
ABG, Arterial Blood Gas; VF, Ventricular fibrillation; VT, Ventricular Tachycardia; ICU, 




Figure 3. Flowchart of FINNRESUSCI study patients, study populations and exclusion 
criteria for all the studies (I-IV). 
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Table 6. Characteristics of patients included in Studies I-IV 
∗ ∗
∗ ∗
Values are presented as numbers (percentages) or median (interquartile range, IQR); SAPS, 
Simplified Acute Physiology Score; APACHE, Acute Physiology and Chronic Health 
Evaluation; CPR, cardiopulmonary resuscitation; ROSC, Return Of Spontaneous 
Circulation; CA, Cardiac Arrest; ICU, Intensive Care Unit; PCI, Percutaneous Coronary 
Intervention; LOS, Length Of Stay, CPC; Cerebral Performance Categories; VF, Ventricular 
Fibrillation; VT, Ventricular Tachycardia; ASY, asystole, PEA, Pulseless Electrical Activity; 




4.2 Study design 
4.2.1 Study I 
This study included all patients from the FINNRESUSCI cohort. The main aims of the 
study were to report the incidence of OHCA patients in intensive care units and to evaluate 
the post-resuscitation care, the use and implementation of therapeutic hypothermia and 
one-year neurological outcome after OHCA in ICUs in Finland.  
The number of Finnish adult population was obtained from Statistics Finland and the FICC 
database was used for ICU admissions and demographic data. All study patients were 
included in the incidence calculations, but only patients who were unconscious at ICU 
admission were included in the final outcome analysis. 
4.2.2 Study II 
This study assessed all arterial blood gas values during the first 24 hours after ICU 
admission and evaluated the possible associations of mean and time-weighted oxygen and 
carbon dioxide partial pressures to one-year neurological outcome during the first 24 hours 
in intensive care. Arterial blood gas values included in this study were collected only from 
comatose and mechanically ventilated patients. Pressure values of PaO2 and PaCO2 were 
defined into four different ranges prior to analysis. The mean 24-hour PaO2 and PaCO2 
values and the proportion of time spent in different oxygen and carbon dioxide categories 
during the first 24-hour were calculated.  
4.2.3 Study III 
In this study magnitudes of inflammatory response and brain injury represented by plasma 
concentrations of IL-6, hs-CRP and protein S-100B were measured during ICU care. This 
study evaluated the levels of measured biomarkers and their associations with the duration 
of ischemia and ability to predict subsequent organ dysfunction and one-year neurological 
outcome. This study was designed to include only patients resuscitated from shockable 
initial rhythm to achieve a homogenous study cohort. 
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4.2.4 Study IV 
This study investigated the prognostic value of hs-TnT levels according to hospital mortality 
and neurological status and mortality after 1 year from cardiac arrest. The correlations of 
admission hs-TnT value to time to ROSC, acute coronary occlusion and pre-existing 
diseases were also analysed. This study was also designed to include only patients 
resuscitated from shockable initial rhythm to achieve a homogenous study population due 
the cardiological aspect of the study design. 
4.3 Data collection 
Study data were collected from the Finnish Intensive Care Consortium (FICC) prospective 
routine database. The additional data of the study were collected prospectively by using 
Internet based study specific case report forms (CRFs) from three different time periods; 
pre-hospital event, daily during ICU care for the first five days and overall ICU care at the 
time of ICU discharge. Daily data collection was terminated if the patient was discharged 
from ICU before day five. 
All the participated 21 ICUs belong to Finnish Intensive Care Consortium (FICC) and to 
the FICC database, which was originally used for benchmarking purposes and currently 
handled by Tieto Healthcare & Welfare Ltd. Data recorded in the routine database includes 
the reason for ICU admission, patient demographics, APACHE II admission diagnosis, 
International Classification of Diseases 10th revision diagnosis, ICU severity scores (SAPS 
II, SOFA, TISS), length of stay, and outcome measures (ICU- and hospital mortality). In 
addition to database routine records, the data from ventilators, patient monitors and 
laboratory systems were automatically transferred to the study database via the clinical 
information systems. 20 ICUs use electronic data management systems and the same data 
validation software (Web Validator, Tieto, Helsinki, Finland). All the participating ICUs 
kept logs of all CA patients admitted to ICU and these logbooks were used to crosscheck 
the number of patients, combine the data of patients treated in more than one ICU during 
the same hospitalization and separate in-hospital CA patients from OHCA study patients. 
The study specific CRFs were developed to complete the data from the database. An ICU 
physician filled the pre-hospital form at ICU admission from the basis of pre-hospital 
medical report. The ICU physician and/or nurse filled the ICU CRFs daily forms for five 
days and at ICU discharge. Data collected with CRF comprised data from chronic health 
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status, pre-existing diagnoses of the heart, lungs or metabolic diseases, and present status of 
performance. These were obtained from the medical history of each patient.  
Outcome data were collected from the FICC database, (ICU- and hospital mortality), and 
long-term mortality data up to 12 months from Statistics Finland. Neurologic outcome data 
according to the Pittsburgh Cerebral Performance Categories (CPC) classification were 
collected by structured telephone interview by one specialist in neurology after 12 months 
from cardiac arrest. Data from laboratory analyses were connected later to the data from the 
database to create different study cohorts. 
4.4 Blood samples 
After written informed consent from the patients or their next of kin, blood samples were 
collected from the study patients at ICU admission (0-6 h), 24 h, 48 h, and 96 h after ICU 
admission. Plasma samples collected to heparin tubes and serum samples to EDTA tubes, 
were kept in room temperature for 30-60 minutes before being centrifuged at 2200 G for 10 
minutes.  Samples were handled and frozen to a minimum of −20°C in the participating 
hospitals, and transferred in the frozen form to Kuopio University Hospital, where they 
were frozen to −70°C. All the samples were thawed at the same time before analysis. 
Routine blood samples were obtained from each patient according to local ICUs standard 
operational protocols and the treating physicians’ decisions and part of the results such as 
for example, arterial blood gases were transferred to the study database via the clinical 
information system. 
4.5 Measurements of biomarkers 
Blood samples were collected at ICU admission (0-6 h) and 24 h, 48 h and 96 h after ICU 
admission. IL-6 and hs-CRP samples were analysed for all time points, despite missing 
admission samples, if the 24 h sample was available. Hs-TnT and S-100B samples in later 
time points were analysed only if admission samples were available. The analyst was blinded 
to patient information for all the laboratory measurements. 
4.5.1 Interleukin 6 and hs-CRP 
IL-6 was measured with a commercially available sandwich-type Enzyme Linked 
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Immunosorbent Assay (ELISA) following the manufacturer’s instructions (R&D Systems, 
Minneapolis. MN. USA). The sensitivity of the assay was 0.7 ng/l. Reference values for IL-6 
is < 5.9 ng/l for all patients. The ELISA method had a measurement range of 0.5 to 300 
ng/l. Concentrations above the upper limit were not diluted, but given a value of 300 ng/l 
in the statistical analyses. CRP was measured with a Cobas 6000 automated analyser with 
reagents (CRP and hs-CRP) from Roche Diagnostics (Penzberg, Germany). Reference 
values for hs-CRP are 0.05-2.5 mg/l for men and 0.05-3 mg/l for women. The analyses 
were performed at the routine laboratory of the Eastern Finland Laboratory Centre at the 
University Hospital of Kuopio, Finland. 
4.5.2 Protein S-100B 
Measurements of S-100B were performed with an automatic immune analyser (Cobas 8000, 
e602, Roche Diagnostics). Reference values for S-100B are < 0.11 μg/l for all patients. The 
total assay variation was less than 2.5%. The analyses were performed at the University 
Hospital in Uppsala, Sweden. 
4.5.3 High-sensitivity troponin-T 
Troponin T in serum samples was measured by the Elecsys TNT hs STAT assay (Roche 
Diagnostics, Penzberg, Germany). The hs-TnT assay has an analytical measurement range 3-
10000 ng/L and the 99-percentile in the healthy population is 14 ng/L. Samples with 
concentrations above the upper limit were diluted before they were re-analysed. The 
analyses were performed at the Akershus University Hospital in Lørenskog, Norway. 
4.6 Disease severity scorings and definitions 
The severity of disease was described by APACHE II242 and SAPS II251 scores, which were 
calculated after 24 hours ICU admission. These scores were used mainly for demographic 
purposes to compare different subgroups in the ICU (I-IV). A modified APACHE II score, 
excluding points for oxygenation, was assessed for demographic purposes and statistical 
analysis (II). Sequential organ failure assessment (SOFA)241 scores (Table 4) were also 
calculated daily to define multiple organ dysfunctions (MODS), but only the first value (24 
h) and SOFA-subscores were used for this purpose later in the analyses (II, III). An extra 
cerebral SOFA-score, excluding points for the neurological component, was also used to 
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define MODS (III)70. The infection status, aspiration, pneumonia and sepsis, during ICU 
care were defined by the treating physicians and local practice in every hospital (I-IV). 
4.7 Outcome measures 
4.7.1 Neurological outcome 
Primary outcome in all studies were long-term neurological outcome determined 12 months 
after cardiac arrest according to the Pittsburgh Cerebral Performance Categories (CPC)223. 
One specialist in neurology, who was blinded to incident, treatment and pre-hospital 
management or during ICU care, contacted all surviving patients, who were not lost to 
follow up, by telephone and made a structured interview to determine the neurological 
outcome. Poor neurological outcome was defined as CPC 3-5 and good neurological 
outcome as CPC 1-2 (Table 3). 
4.7.2 Mortality 
ICU and hospital mortality data, which represent the short-term outcome, were obtained 
from the FICC database and 90-day and 12-month mortality from the Finnish Population 
Register Centre using the social security number of each study patient.  
4.8 Statistical methods 
Categorical data are presented as absolute numbers and percentages, and continuous data as 
median values with interquartile ranges (IQR, 25th-75th percentiles). Categorical variables 
were compared by Pearson´s chi-square test or Fisher´s exact test when appropriate. 
Kolmogorov-Smirnov was used to assess non-normal distribution of continuous variables, 
the Mann-Whitney U-test for comparing group differences and Kruskall-Wallis when 
comparing distributions between more than two groups. 
The first measured partial pressures of O2 and CO2 were considered to represent values 
from admission to the first measurement time point. Time intervals between PaO2 and 
PaCO2 were calculated and measured values assumed to remain constant until the next time 
point of measurement. These values and time intervals were used for calculations for time 
spent in different O2 and CO2 categories (II).  
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To evaluate the prognostic values of measured biomarkers, receiver-operating characteristics 
(ROC) curves and areas under curves (AUC) were calculated with 95% confidence intervals 
(III, IV). When comparing biomarker levels in different outcome groups, repeated measures 
analysis of ANOVA was used after adjusting for non-normal sphericity and the Spearman 
rank correlation factor was used for correlation calculations between variables (III). 
Multivariable logistic regression analysis were constructed and used to evaluate odds ratios 
for independent factors associated with neurologic outcome (I-IV), organ dysfunction (III) 
and mortality (IV) and to evaluate the additive predictive power of biomarkers, the category 
free net reclassification index (NRI) was calculated (III). The Wilcoxon matched-pairs 
signed-rank test was used to assess changes biomarker levels between different time points 
(IV). The Hosmer-Lemeshow goodness of fit test was used to assess the calibration of 
models created (II) and propensity analysis was performed and used to compare two 
separate groups (I). A p-value of <0.05 was considered significant in all analysis (I-IV).  
The statistical analysis was performed using IBM SPSS statistics version 19-20 (SPSS 
Chicago, Ill., USA), Graph Pad Prism version 6.0 and R version 3.0.1 for Windows (R 
Foundation for Statistical Computing, Vienna, Austria) and MedCalc for Windows, version 






5.1 Incidence (I) 
The total number of ICU admissions to the participating ICUs during the 1-year study 
period was 17 540. Cardiac arrest was recorded as the cause for ICU admission in 829 
(4.7%) cases, which includes 548 individual adult OHCA patients (Fig 2). The population-
based incidence of OHCA treated in ICU, using the numbers of adult inhabitants in the 
participating hospital districts as a reference population, was 13/100 000/year. Of those 548 
patients, 311 patients (56.8%) were resuscitated from shockable initial rhythm (VF/VT) 
corresponding to an incidence of 7.4/100 000/year and 237 patients (43.2%) had a non-
shockable initial rhythm, (asystole or PEA), corresponding to an incidence of 5.6/100 
000/year. (I).  
5.2 Temperature management (I) 
 
Out of total 548 patients 44 (8.0%) patients were reported to be conscious and 504 (92.0%) 
were unconscious at ICU admission and therefore considered for therapeutic hypothermia 
(TH). TH was induced to a total of 311 patients comatose at ICU admission, 241/281 
(85.8%) patients resuscitated from shockable rhythms and 70/223 (31.4%) patients 
resuscitated from non-shockable rhythms. The distribution of the patients divided by initial 









OHCA, Out of Hospital Cardiac Arrest; VF, Ventricular Fibrillation; VT, Ventricular 




Endovascular cooling devices were used for hypothermia induction and maintenance in 247 
(79.4%) and surface cooling devices in 58 (18.6%) cases. Five patients were cooled with 
other surface cooling methods and one patient with only ice-cold intravenous fluids. Ice-
cold intravenous fluids were also used as a start of induction in the pre-hospital setting or as 
an additional method for cooling devices in 50 (16.1%) patients. The target temperature was 
set to 33ºC in 300 (97%) patients and temperatures of 32-34ºC were achieved in a median of 
111 (70-180) minutes from the start of hypothermia induction. Targeted temperature 
maintenance time was 24 hours in 231(74.3%) patients (range 0-47 h) and the median (IQR) 
rewarming time from hypothermia to normal temperature was 9 (6-12) hours. Reasons for 
withholding TH in unconscious patients resuscitated from VF/VT (40) were based on 
clinical grounds and decisions according to the current guidelines (Table 7). 
 
 
Table 7. Reported reasons from treating ICU physicians for withholding therapeutic 
hypothermia (TH) from out-of-hospital cardiac arrest (OHCA)-VF/VT patients who were 
comatose at ICU admission. 
ICU, Intensive Care Unit; VF, Ventricular Fibrillation; VT, Ventricular Tachycardia; ROSC, 
Return Of Spontaneous Circulation; *Reporting multiple reasons was possible in individual 
patients. 
 
The total number of patients across each participating study ICU varied between 2 and 74 
patients/year and the use of TH varied between 32% and 100% of all OHCA patients and 
between 46% and 100% with OHCA-VF/VT (Table 8).  
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Table 8. The numbers of out-of-hospital cardiac arrest patients, distribution of initial 
rhythms and therapeutic hypothermia treatments in individual FINNRESUSCI study units 
(Vaahersalo et al., unpublished results).  




5.3 Blood gases (II) 
Arterial blood gases (ABG) were measured, electronically recorded and validated in the 
database from a total of 468 patients. Of these, 409 patients fitted the inclusion criteria 
(comatose at admission, mechanically ventilated and one-year neurological outcome data 
available) and constituted the study cohort for ABG analysis during the first 24 hours of 
ICU care (Fig 2). The median amount of ABG measurements/patient was eight (IQR 6-11). 
5.3.1 Oxygen 
Hyperoxia exposure, defined by arterial oxygen (PaO2) values higher than 40 kPa 
(300mmHg), was found in 24 (6%) patients. Mean FiO2 was 46%, median (IQR) 41% (37-
51), during the first 24 h of ICU care and there was no different in patient group with good 
or poor outcome. The proportions of time in different oxygen ranges are presented in 
Figure 5. PaO2 values were higher in patients with good outcome than those with poor 
neurological outcome (Table 9), but the mean PaO2 tension did not associate with better 
outcome OR 1.006 (95% CI, 0.998-1.014) and multivariable analysis showed no association 




Figure 5. Proportion of mean times (SD) in different oxygen categories in mechanically 





Table 9. Median values (IQR) of arterial PaO2 during the first 24 h in ICU after OHCA 
divided by one-year neurological outcome. 
 
Values are presented in mmHg = 7.5 kPa; IQR, Interquartile range; ICU, Intensive Care 
Unit; OHCA, Out-of-Hospital Cardiac Arrest 
5.3.2 Carbon dioxide 
The mean arterial carbon dioxide (PaCO2) values during the first 24-hour did not differ 
between good and poor neurological outcome groups but the mean PaCO2 value predicted 
independently good outcome with OR 1.054 (95% CI; 1.006-1.104, p=0.027). Also the time 
spent over 6 kPa (45 mmHg) associated with good neurological outcome after 12 months in 
multivariable analysis OR 1.015 (95% CI; 1.002-1.029, p=0.024). This finding persisted in 
sensitivity analysis, when only TH treated patients were included in the analysis. Patients 
with the highest mean PaO2 and PaCO2 values in tertiles were found to have better 
outcome than predicted.  The OR for good outcome was 3.2 (95% CI; 1.1-9.2, p=0.033) 






5.4 Biomarkers after cardiac arrest 
5.4.1 IL-6 and hs-CRP (III) 
Elevated levels of serum IL-6 and hs-CRP demonstrate the inflammatory response after 
cardiac arrest and levels changed over time in all patients. IL-6 was already elevated at ICU 
admission and reached the highest values at 48 hours, while hs-CRP elevated later and 
continued to increase until 96 hours after ICU admission (Fig 6). Admission values of IL-6 
were higher in patients with poor neurologic outcome and associated over time with ROSC 
and subsequent organ dysfunction (p<0.001), while hs-CRP values were not. Admission IL-
6 predicted poor neurological outcome with AUC 0.711 and extra cerebral organ 
dysfunction with AUC 0.679. Admission values of IL-6 and associations with extra cerebral 




Figure 6. Evolution of inflammatory biomarkers IL-6 and hs-CRP following CA in patients 













In multivariate logistic regression analysis, (including time to ROSC, age, history of coronary 
artery disease (yes/no), awake (yes/no), witnessed CA (yes/no), and admission values IL-6 
and S-100B), only time to ROSC, age and admission IL-6 were independently associated 
with poor neurological outcome (Table 10). By adding IL-6 and S-100B to the basic variable 
model with AUC 0.820 (including age, time to ROSC, history of coronary artery disease 
(yes/no), awake (yes/no), the AUC improved to 0.842, but only adding IL-6 was statistically 




Table 10. Independent predictors of poor neurological outcome (CPC 3-5) in multiple 
logistic regression analysis 
CPC; Cerebral Performance Category, OR; Odds Ratio, CI; Confidence Interval, IL-6; 
Interleukin-6 
 
5.4.2 S-100B (III) 
S-100B values decreased over time in all OHCA patients, but the values were higher in 
patients with poor outcome (p<0.001). S-100B associated also with a longer time to ROSC 
(p=0.002), and the AUC to predict extra cerebral organ dysfunction for admission value of 
S-100B was 0.574. The corresponding AUC values for S-100B to predict poor neurological 
outcome were 0.699 at admission, 0.693 at 24h, 0.700 at 48h and 0.712 at 96h and S-100B 
did not predict outcome independently in the multivariable analysis (Table 10). By adding S-
100B to the basic variable model with AUC 0.820 (including age, time to ROSC, history of 
coronary artery disease (yes/no), awake (yes/no), the AUC improved to 0.830, but it did not 




Table 11. Values of S-100B on admission and at 24h divided by one-year neurologic 
outcome and organ dysfunction, defined by CPC extra cerebral SOFA score. 
CPC; Cerebral Performance Category, SOFA; Sequential Organ Failure Assessment 
5.4.3 Hs-TnT (IV) 
Admission hs-TnT was analysed from 155 OHCA patients, 152 (98%) resuscitated from VF 
and 3 (2%) from VT. The numbers of samples analysed in later time points were 150 at 24h, 
138 at 48h and 107 at 96h after ICU admission. The median (IQR) level of admission hs-
TnT was 415 (199-916) ng/l, with a range of 18-17837 ng/l, indicating significant increase 
in all successfully resuscitated patients admitted to ICU. Admission hs-TnT levels correlated 
positively with time to ROSC (r=0.47, p<0.001) and the median value (IQR) of admission 
hs-TnT among patients with evidence of acute coronary occlusion (n=15) was significantly 
elevated 1.497 (753-8875) ng/l compared to 387 (182-815) for all other patients (p<0.001). 
Admission hs-TnT levels, median (IQR), were higher in patients with poor one-year 
neurological outcome vs. good neurological outcome 739 (191-1061) ng/l vs. 334 (195-716) 
ng/l (p=0.028) and one-year non-survivors compared to survivors, 747 (206-1061) ng/l vs. 
345 (184-740) ng/l (p=0.023), but there was no statistical difference between hospital 
mortality groups. Reduction of hs-TnT levels from admission to later time points was 
demonstrated in most patients, but there were no differences in hs-TnT dynamics according 
to mortality or outcome. 
 
In the ROC curve analysis, admission hs-TnT is associated with one-year mortality (AUC 
0.61) and one-year neurological outcome (AUC 0.60), but did not have the same influence 
on hospital mortality (AUC 0.59). Hs-TnT levels measured after 24 hours from ICU 
admission did not improve the predictive power of admission hs-TnT. After the first 24h 
when the Simplified Acute Physiology Score (SAPS) was available, SAPS II predicted 
outcome more accurately (Table 12). Admission hs-TnT levels were not associated with 
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hospital mortality OR 1.25 (95% CI 0.95-1.64, p=0.12), one-year mortality or neurological 
outcome OR 1.26 (95% CI 0.97-1.63, p=0.008) in the logistic regression analysis, while 
several other previously known risk variables (age, time to ROSC, history of coronary artery 
disease or heart failure) associated with mortality and neurological outcome. 
  
 
Table 12. Prognostic values of SAPS II score and hs-TnT values measured < 24 h from 
ICU admission as assessed by ROC analysis.  
SAPS, Simplified Acute Physiology Score; ICU, Intensive Care Unit; ROC, Receiver 
Operating Characteristic; CPC, Cerebral Performance Categories; AUC, area under the 
curve; CI, confidence interval 
 
 
5.5 Outcome (I) 
Out of 548 ICU treated OHCA patients, 234 (42.7%) were alive at 12 months after CA. Out 
of comatose (504) patients, 12-month outcome data were not available for 9 (1.8%) patients 
and total of 13 (2.4%) patients were lost to follow up. Overall ICU mortality was 21.7%, 
hospital mortality 45.3% and 90-day mortality 51.3%. Median (IQR) length of stay (LOS) in 
ICU was 2.6 (1.5-4.2) for all patients and was significantly longer in patients treated with TH 
3.3 (2.4-5.8) than in patients treated without TH 1.2 (0.8-1.9). 
 
Length of stay, mortality and neurological outcome of all FINNRESUSCI patients, 
comatose and conscious, are presented in Table 13.   
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Table 13. Outcome of FINNRESUSCI patients 
∗
∗
ICU, Intensive Care Unit, LOS, Length Of Stay; IQR, Interquartile Range; CPC, Cerebral 
Performance Categories; *Neurological outcome (CPC) missing in 13 (2.4%) patients 
 
5.5.1 OHCA patients with shockable and non-shockable rhythms 
Out of 281 OHCA patients resuscitated from VF/VT and unconscious at ICU admission, 
147 (52.9%) had favourable one-year neurological outcomes (CPC 1-2). Of those patients 
138 were treated with TH, representing favourable outcomes in 57.3% (138/241) patients. 
Of the comatose VF patients treated without TH, 22.5% (9/40) survived with good 
neurology. In patients resuscitated from ASY/PEA, the proportion of good neurological 
outcome was 19.4% (13/70) in patients treated with TH and 16.0% (24/153) without TH 
respectively. The proportion of good neurological outcomes in ASY/PEA patients was less 
than in VF/VT. TH treatment did not improve outcome in patients resuscitated from non-
shockable rhythms. Only age and higher APACHE II score, but not the use of TH was not 
associated with neurological outcome in this group of OHCA patients. Length of stay, 
mortality and neurological outcomes of unconscious patients according to initial rhythm 
and TH treatment, are presented in Table 14. 
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Table 14. Outcome of unconscious OHCA patients (n=504) divided into initial rhythms 
and use of TH groups 
Values are presented as numbers (percentages) or median (interquartile range, IQR); 
OHCA, Out-of-Hospital Cardiac Arrest; TH, Therapeutic Hypothermia; VF, Ventricular 
Fibrillation; VT, Ventricular Tachycardia; PEA, Pulseless Electrical Activity; LOS, Length 
of Stay; ICU, Intensive Care Unit; CPC; Cerebral Performance Categories, *Neurological 
outcome (CPC) missing in 9 (1.8%) patients. (3 VF/VT, 6 PEA/asystole), 
 
The patients were treated in 21 different ICUs and the number of patients in each study 
ICU varied between 2 and 74 patients. Hospital mortality varied between 18 and 71% for 
individual study sites, but there was no correlation between ICU size or number of treated 
patients in ICU and hospital mortality or outcome. One-year neurological outcomes of each 





Table 15. One-year neurological outcomes of OHCA patients divided by initial rhythms in 
individual FINNRESUSCI ICUs (Vaahersalo et al., unpublished results) 
Values are presented as numbers (percentages); OHCA, Out-of-Hospital Cardiac Arrest; 
ICU, Intensive Care Unit; CPC, Cerebral Performance Categories; *Representing number of 
missing patient for one-year neurological outcome data 
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6 DISCUSSION 
6.1 Incidence of OHCA (I) 
 
The incidence of OHCA patients in ICU in this study (13/100 000/year) is in agreement 
with a previous Finnish study by Oksanen at al. reporting an incidence of 15/100 000 
inhabitants/year33. The incidence is also in agreement with previous Finnish studies 
reporting the overall incidence of OHCA5,26,30,31,252, while the reported rate of ROSC and 
survival to hospital is 30-35%  in Scandinavia5,26,32. Of those OHCA patients who survive to 
hospital admission, only selected patients are treated in ICUs26,32. Local protocols, hospital 
resources and optional units for OCHA patients affect the selection of patients for ICU 
care, when intensive care is unlikely to benefit the patient. In some hospitals nearly all 
OHCA patients are treated in ICU despite pessimistic prognoses. In this study 56.8% of 
patients were resuscitated from shockable initial rhythm, but a variation between 
participating ICUs and portion of VF patients (0%-91%) existed. The number of OHCA-
VF patients also varied between university hospital ICUs (50%-91%), which is comparable 
with other single hospital studies (65%-90%) reporting the results for OCHA patients 
treated with therapeutic hypothermia32,83,127. 
 
The type of EMS system mostly explains the incidence of VF, because it is likely that 
most CA patients have shockable rhythms at the time of collapse, but by the time of the 
first ECG, these rhythms have deteriorated to PEA or asystole2,253,254. It has been shown 
that if the rhythm is recorded soon after collapse, with public access defibrillators or EMS 
personnel on site, the proportion of VF can be as high as 76%42,255. So the time to first 
ECG recording and possible defibrillation, usually by EMS personnel, affects the VF 
incidence and also the portion of VF patients in ICU. In this study, the highest proportion 
of VF patients were in ICUs covering the largest cities and urban areas, and not hospitals in 
the rural area where response times of EMS systems can be assumed to be longer5. The 
proportion of VF as the initial rhythm has also decreased over the last few years28,30,256,257.  
Improved care of coronary artery disease and prevention have been suggested to explain 
this decrease258-261. VF decrease has been shown to be higher among patients with 
unwitnessed OHCA who collapsed at home257, which may also lead to differences in the 
numbers of VF patients between ICUs. 
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6.2 Temperature management (I) 
Therapeutic hypothermia, temperature control or targeted temperature management has 
been in clinical practice in every ICU for over a decade in Finland33,95. ILCOR issued an 
advisory statement recommending TH for all OHCA patients resuscitated from VF already 
in 200316, and according the ERC Guidelines for Resuscitation, TH has been recommended 
for OHCA VF patients since 2005125. In this study nearly 86% of the comatose VF/VT 
patients were treated with TH, thus the usage of TH in Finland has increased significantly 
from 200795. The nationwide use of TH has not been reported in the literature, but the 
proportion of TH-treated VF patients is one of the highest compared to previous reports 
from single hospital or registry studies83,129,131,239,262. TH or TTM is administered to 
practically all OHCA-VF patients in Finland, while withdrawal of TH from VF patients is 
based on clinical judgment decisions (Table 7).  
The ILCOR advisory statement also suggested TH for all comatose CA patients chosen to 
intensive care in 2003, and this recommendation was adopted in the European guidelines 
later, by the Scandinavian clinical practice guidelines in 2009103, and by ERC for all CA 
patients in 201018. In this study 61.7% of unconscious patients were treated with TH, and 
31.8% of non-shockable patients, which is a reasonable result, considering the fact that the 
ERC guidelines were published in October 2010 during the study period. Adherence to the 
guidelines concerning the use of TH has been reported for 79% of ERC Hypothermia cases 
in a cardiac arrest registry study from 19 sites in Europe129 and 70% in a study by Lindner et 
al. from Norway, where cooling has been suggested for all CA patients since 2004262. 
Patients were treated to a target temperature of 33°C in 97% and for 24 hours in 74% cases, 
according to guidelines of the time. Previous RCTs of TH from the beginning of the 20th 
century have some weaknesses and limitations13,14. The HACA study has been criticized for 
patients temperature in normothermic control group, which seems to be well over 37°C, 
meaning their temperatures were hyperthermia not normothermia 13 and the study by 
Bernard et al. has been called pseudo-RCT because of methodological reasons14. A recent 
RCT study of 950 OHCA patients randomized the patients to 36 hours of temperature 
control either at 33°C or 36°C17. This Targeted Temperature Management (TTM) trial 
reported no difference in neurological outcome or mortality between the groups treated at 
33°C or at 36°C. Hyperthermia was prevented for 72 hours in both groups. Despite these 
results, the optimal temperature and duration of TH or temperature control is still 
unknown263. According to the ILCOR’s latest recommendation104, temperature should 
maintain constant between 32° and 36° for at least 24 hours for adults after OHCA with 
initial shockable rhythm. This statement reflects the latest ERC and ESICM 
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recommendations and guidelines264. These guidelines suggested that TTM should also be 
given to comatose adults after OHCA resuscitated from non-shockable rhythm and IHCA 
patients, despite the evaluation of literature by the GRADE methodology ending up with 
very low-quality of evidence19,104. 
 
Endovascular cooling devices were mainly (79%) used for induction and maintenance of 
hypothermia in Finnish ICUs, which is also recommended in the very latest ERC guidelines 
for controlling temperature during TTM19. The internal devices enable better control for 
temperature than other techniques153,154, but there is no evidence for better survival with 
internal devices. Ice-cold fluids were used as an additional cooling method and in pre-
hospital setting for 50 (16%) patients, which according the ERC’s latest guidelines19 is no 
longer recommended. Increased risk of re-arrest was reported during transport to hospital 
in three studies148,149,151. The largest and the latest of these studies also reported increased 
risk of pulmonary oedema in a pre-hospital ice-cold fluid cooling group (RR, 1.34; 95% CI, 
1.15-1.57)151, and the no benefit of pre-hospital cooling has so far been shown. The 
temperature management complied very well with the current international guidelines 
during the study period and, except for the minor use of ice-cold fluids, the temperature 
management was also in agreement with recent international recommendations and 
guidelines19,104. 
 
6.3 Blood gases (II) 
6.3.1 Oxygen 
The findings of Study II indicated that hyperoxia exposure is rare (6%) after CA in Finland. 
Additionally, hyperoxia was not associated with poor outcome, instead a combination of 
moderately elevated oxygen and CO2 levels were associated with good neurological 
outcome. 
In studies reporting the association of hyperoxia with mortality, the prevalence of hyperoxia 
has been between 10% and 40%158,160,265,266, significantly higher than the prevalence in Study 
II.  The prevalence of hyperoxia was also high (41%) during the first 24 hours in ICU in one 
single centre study, which also reported hyperoxia association with longer times to ROSC 
and delays to ICU admission and cardiac arrest location163.  
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Hyperoxia after CA has been shown to associate with increased mortality in large 
observational studies, when only single values of PaO2 were analysed - either the highest or 
the first value158,159. These studies did not control the severity of ischemic insult, PCAS or 
the ICU care process, which is a major limitation to these results, because hyperoxia is 
associated with longer time to ROSC and longer delays for ICU admission163. In studies 
where these factors were controlled, no associations with hyperoxia and mortality were 
found160,266. In Study II the mean values of PaO2 during the first 24 hours in ICU were used 
for analyses instead of single values. The mean PaO2 values were higher for patients with 
good outcomes, but the values did not predict outcome, neither did time spent in different 
PaO2 levels have any influence on outcome.  However, the prevalence of hyperoxia 
exposure was so low, that it is impossible to rule out a harmful effect of hyperoxia on 
outcome based on these study results.  
A recent registry study from the Netherlands comprising over 5000 patients reported a U-
shaped relationship between partial pressures of O2 and hospital mortality after adjustment 
for confounding factors. Only hypoxia was independently associated with hospital mortality 
with an OR of 1.34 (95% CI 1.08-1.66) but not hyperoxia, OR 1.13 (95% CI 0.81-1.57)267. A 
recent study also reported the disadvantages of severe hyperoxia, but it also reported an 
association with improved organ function (defined by a SOFA score at 24 h) and moderate 
hyperoxia268. According to this study, the relationship between hyperoxia and outcome 
seems not to be linear or dose-dependent, but poor outcome may occur only after oxygen 
tension exceeds a certain threshold. The results of Study II showed a combination of mild 
hyperoxia with mild hypercarbia to associate with better than predicted neurological 
outcome. These results are in close agreement with the recent studies by Elmer and 
colleagues268 and Helmerhorst and colleagues267. The number of hyperoxia studies with CA 
patients are limited and include several confusing factors, so the clear effect of hyperoxia or 
the optimal levels of oxygen partial pressures are still to be determined161. While the effects 
of hyperoxia are still unknown, hypoxia is definitely harmful for CA patients158,160,267, which 
indicates that there is a need for careful monitoring of oxygen levels to avoid possible 
hypoxia. 
 
6.3.2 Carbon dioxide 
In Study II it was showed that the mean 24-hour PaCO2 value was an independent predictor 
of favourable one-year neurological outcome. Also time spent over 6 kPa (45 mmHg) of 
PaCO2 was associated with good one-year neurological outcome in our multivariable model. 
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There are very limited data on the relationship between concentrations of CO2 and 
outcome after CA and the available data give conflicting results. The positive association of 
mild hypercapnia in Study II is in close agreement with a large observational study 
containing over 16 000 patients, which reported an independent association between 
hypocapnia and hospital mortality, but an increased rate of patients discharged in a 
hypercapnia group compared to a normocapnia group, (OR 1.16)92. A large registry study 
from the Netherlands found a U-shaped relationship between hospital mortality and PaCO2 
levels, but when compared to normocapnia, only hypocapnia was a statistically significant 
predictor for hospital mortality (OR 1.37)) and not hypercapnia (OR 1.1)267. Both these 
studies used only single ABG values, the worst oxygenation time in the first 24 h, in the 
analyses and robust short term outcome variables as an outcome endpoint in contrast to 
Study II, where the mean value of PaCO2 and one-year neurological outcome were used to 
reduce concern about limitations observed269 in a study by Schneider and colleagues92  
The positive association of mild hypercapnia is in contrast with a single centre study 
from the USA, which reported both hypocapnia and hypercapnia being independently 
associated with poor neurological function, OR 2.43 (95% CI, 1.04-5.65) and 2.20 (95% CI, 
1.03-4.71), respectively91. This study also used one ABG value to define patients to 
hypocapnia or hypercapnia groups at any time point during the first 24 h and the majority 
of patients were IHCA patients, which is major difference compared to Study II, which 
included only OHCA patients. 
There are several possible explanations for the positive association between mild 
hypercapnia and one-year neurological outcome. Elevated PaCO2 levels have been shown to 
be associated with less brain damage in animal models by increasing blood flow and 
diminishing local brain hypoxia in brain ischemia166. Cerebral blood flow could be decreased 
after CA in the early phases of PCAS270 due the impairment of autoregulation or  an 
imbalance between local vasoconstrictors and vasodilators. CO2 is a well-known vasodilator 
of cerebral veins and mild hypercapnia might reverse these abnormalities. The upper normal 
range of PaCO2 increased cerebral blood flow and decreased cerebral lactate compared to 
the lower normal range of PaCO2271. CO2 also has anticonvulsant effects171 and possible 
alkalosis in brains induces seizures in an animal model272. In contrast hypercapnia is against 
the guidelines in neurocritical care for traumatic brain injury patients as it results in 
increased intracranial pressure (ICP) and brain oedema273, which correlate with 
unfavourable outcome with traumatic brain injury (TBI) patients274. ICP is not routinely 
monitored in CA patients and its role is unclear in PCAS, but also hypocapnia may be 
harmful for TBI patients, causing vasoconstriction and ischemia52,275.  
Hypocapnia and hypercapnia are common (18%-22%, 35%-41%) after CA during ICU 
care92,267 and thus, a ventilation strategy is a relevant intervention after CA and it might have 
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a great influence on outcome. Hyperventilation leads to hypocapnia, which causes cerebral 
ischemia165,173, which can be controlled using a mechanical ventilation strategy. According to 
the international guidelines, all CA patients should be treated with temperature control or 
TTM in ICU19.  Therapeutic hypothermia decreases metabolism and reduces the production 
of CO2, which easily leads to hyperventilation in patients treated with TH176. 
Hyperventilation has been shown to reduce cerebral tissue oxygenation significantly during 
TH174 and an association between hypocapnia and poor neurological outcome has been 
documented in observational registry studies91,92.  
To date there are no prospective and randomized studies to clarify the optimal ventilation 
strategy and the ERC guidelines recommend normocapnia after cardiac arrest19, but 
according to results of Study II and the literature it seems that hypocapnia is more 
dangerous than mild hypercapnia, which may be even beneficial after CA.   
  
6.4 Biomarkers (III-IV) 
6.4.1 IL-6 and hs-CRP 
The findings of Study III showed that admission values of IL-6, but not of hs-CRP are 
associated with subsequent organ dysfunction and predict one-year neurologic outcome 
with an OR of 1.006 (95% CI 1.00-1.01/ng/l, p=0.046).  
Many inflammatory biomarkers have been investigated in critical care patients180. In 
these studies high levels of IL-6 have been shown to correlate with organ dysfunction and 
mortality in sepsis190,191. Cardiac arrest, global ischemia and successful ROSC lead to 
generalized activation of a systemic inflammatory response and release a profile of 
inflammatory biomarkers and clinical symptoms after CA that are similar to those of 
sepsis66. The magnitude of this inflammatory response is the determinant factor in 
developing PCAS and its severity7. The severity of PCAS is dependent on the severity of 
ischaemic insult but the ischemia and activation of inflammatory response increases the risk 
of multiple organ dysfunction. Development of organ dysfunction after CA will worsen the 
patient´s outcome8 and multiple organ dysfunction, defined by the extra-cerebral SOFA 
score, after cardiac arrest is an independent predictor of hospital mortality70. 
The magnitude of inflammatory response was demonstrated in Study III by elevated 
levels of IL-6 and hs-CRP in all OHCA-VF patients, but only IL-6 values were higher in 
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patients with poor one-year neurological outcome (p<0.001). This result is in close 
agreement with one relatively small study which reported that elevated plasma 
concentrations of IL-6 and hs-CRP correlated with patients outcome196. A similar release 
profiles of CRP have been shown in one paediatric study, CRP levels were elevated in both 
survivors and nonsurvivors after CA193. In Study III hs-CRP levels did not differ between 
outcome groups, this is in contrast to a study by Samborska-Sablik196. This study also 
included IHCA patients (25/46), which may explain the difference in hs-CRP results 
compared to Study III. Similar release profiles, the late release of hs-CRP and CRP and 
earlier release of IL-6 or procalcitonin have been reported in previous studies142,244. 
 The findings in Study III, especially the results for admission IL-6 are in close 
agreement with a study by Annborn et al.244. In this study high levels of procalcitonin (PCT) 
at 12 h correlated strongly over time with ROSC, correlation coefficient 0.64, and associated 
with circulation SOFA subscore, surrogate markers of PCAS. Respectively the admission 
IL-6, correlation coefficient to time to ROSC was 0.387 and high values associated with 
circulation and renal SOFA subscores. When comparing IL-6 and PCT as predictors for 
neurological outcome in ROC analysis, PCT showed high accuracy at 12 h and at 24 h after 
cardiac arrest with AUCs of 0.88 and 0.86. The corresponding AUC values for IL-6 were 
lower, being 0.71 at admission and 0.64, 24 h after admission. On the other hand, admission 
IL-6 was independently associated with poor outcome (OR 1.006/ng/l) along with time to 
ROSC and age in multivariable analyses (Table 10). 
Therapeutic hypothermia may cause bias in biomarker studies, because it influences 
inflammatory biomarker release, suppressing the release of CRP, but neither IL-6 nor PCT 
were unsuppressed142. The majority of the patients (91%) in Study III were treated with TH 
and only TH treated patients were included in the sensitivity analysis to remove any possible 
bias of TH. The association was non significant (p=0.07 with TH treated patients (OR 
1.005 ng/l)).  
6.4.2 S-100B 
Study III showed that S-100B values were higher at all time points in patients with poor 
one-year neurological outcome. S-100B does not have adequate predictive value for 
neurological outcome (AUCs 0.693-0.712) or subsequent multiple organ dysfunction with 
an AUC of 0.574 for admission S-100B. 
S-100B and NSE are the most studied neurological biomarkers for predicting outcome 
after CA177. Several studies have found high levels of NSE or S100B in patients with poor 
neurologic outcome before the time of TH treatment187,198,276,277. Clinical implementation 
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and usage of TH has changed to roles of these biomarkers as clinical tools for outcome 
prediction181. 
The Study III results concerning S-100B contrast with a recent study that reported 
superior predictive value for S-100B when compared to other neurological biomarkers in 
TH treated patients188. This study reported a peak sensitivity of 87% at 24 h with 100% 
specificity. The results of Study III are supported by a registry study by Zellner and 
colleagues205. In this study S-100B predictive value was reported to be comparably poor for 
S-100B at admission (AUC 0.67, the value for Study III was AUC 0.699) and at 24 h (AUC 
0.74) and (AUC 0.693), respectively. A previous study from Finland181 with OHCA-VF 
patients treated with TH also reported a comparable prognostic value for S-100B at 24 h 
(AUC 0.65) to that of Study III. Studies by Mörtberg and Zellner included IHCA patients 
(11%-13%) in their analyses and in the study by Mörtberg a relatively small number of 
patients in contrast to Study III included only OHCA-VF patients. Despite the fact that all 
the patients were treated with TH, the heterogeneous study population may have influenced 
the outcome data.  
An interesting finding of Study III was that despite S-100B levels being associated with 
time to ROSC, the levels did not associate with subsequent organ dysfunction, while 
admission levels of S-100B were significantly higher in patients with poor neurological 
outcome. It is probable that multiple organ dysfunction correlates with the magnitude of 
inflammatory response and neurological injury associates with outcome independently.   
6.4.3 Hs-TnT 
Study IV showed that hs-TnT levels were above the 99th percentile of normal values, being 
14 ng/l for all OHCA-VF patients on ICU admission (range 18 to 17837 ng/l). Hs-Tnt 
values were higher among patients with unfavourable one-year neurological outcome and 
non-survivors, but hs-TnT did not give additional value for prognostication compared to 
the traditional model of well-known risk factors. 
Cardiac troponins are in clinical use for diagnostic purposes for acute myocardial 
infarction (AMI)211. Elevated troponin levels have been shown to correlate to the prognosis 
for AMI patients278, but the relevant clinical additional information for OHCA patients is 
still missing177. Previous studies with troponins for CA patients mainly report that troponins 
are markers that can be used to diagnose acute coronary occlusion220,221,279-281, but no 
relationship between this ability and patient outcome has been reported. A study220 on 
admission hs-TnT reported no difference in ICU mortality between patients with or without 
acute coronary occlusion, despite median hs-TnT at admission being reported to be three 
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times higher in the coronary occlusion group (1184 vs. 351 ng/l). The median hs-TnT was 
at admission 551 ng/l (IQR 203-2551) for all the OHCA patients. These results are in 
agreement with Study IV, which reported a median Hs-TnT at admission of 415 ng/l for all 
patients, respectively in patients with or without acute coronary occlusion (1497 ng/l vs. 387 
ng/l).  
In Study IV several factors, but not admission hs-TnT, were associated with mortality or 
one-year poor neurological outcome, but only age and time to ROSC were independent 
predictors of poor outcome in multivariate analysis. The limited prognostic value of hs-TnT 
can be explained in many ways, but probably the main reason is the aetiology of deaths after 
CA. Brain injury is a well established cause of deaths, especially during follow up periods, 
while myocardial dysfunction is a minor cause of deaths (25%-35%) and mainly responsible 
for very early deaths after CA11,12. Since troponin T has been shown to be elevated by 
several other factors other than coronary occlusion, like chest compressions and 
defibrillations217,218,281, it can be assumed that hs-TnT is similarly affected. So increased 
levels of hs-TnT do not represent only AMI, but may be elevated due to transient reasons 
with the levels decreasing quickly. The reduction in hs-TnT levels were clearly seen in most 
patients in Study IV from admission to 24 h, but the dynamics did not correlate with the 
outcome. It is also very probable that 34 (22%) patients went to coronary angiography and 
those treated with PCI 15 (10%) in Study IV, were patients with other acute clinical signs of 
AMI (ST-elevation on ECG) and their coronary occlusions had been treated. Early 
revascularization after CA may have been prevented the following of myocardial 
dysfunction, which has been shown to be beneficial in many observational studies78,85,221,240. 
It seems that despite the fact that AMI is the main cause for CA and that hs-TnT and other 
troponins are able to identify coronary occlusion and AMI, it has no prognostic value for 
outcome prediction.   
6.5 Outcome (I-IV) 
 
In this study one-year neurological outcome was the main outcome variable measured in all 
(I-IV) independent studies. Mortality was used as an outcome endpoint in Studies I and IV, 
while multiple organ dysfunction was used for an additional endpoint in Study III. Overall 
mortality and neurological survival are highly dependent on the study population. Patient 
related factors (age, previous state of health, cardiac arrest location, in- or out-of hospital) 
and resuscitation key predictors witnessed CA, bystander CPR, initial rhythm and delays in 
response times are related to survival, which makes studies and results hard to compare. In 
the meta-analysis studies from 1984 to 2008 reporting factors associated with outcome, 
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pooled rate of survival for hospital discharge in all OCHA patients across various 
populations and EMS systems was reported to be 7.6% (95% CI 6.7-8.4)1. According to the 
same study successful resuscitation and survival from pre-hospital scene to hospital 
admission was reported to be 23.4% (95% CI 21.1-26.6). The proportion of VF as an initial 
rhythm and short delays in the EMS systems in study populations are highly dependent on 
reported survival rates, because OR for survival in locations with EMS with response times 
less than 8 minutes was 5.9, compared to 2.4 in locations with response times over 8 
minutes1. 
Because of the more heterogeneous aetiology of cardiac arrest and generally worse outcome 
in patients resuscitated from non-shockable initial rhythms, outcome is usually reported in 
OHCA-VF and non-VF patients separately. Studies III and IV included only OHCA-VF 
patients in their analyses and reported results only for this group of patients.  
 
6.5.1 Outcome of OHCA-shockable patients (I) 
 
In Study I the hospital mortality of unconscious OHCA-shockable patients (34%) is in 
agreement with previous studies15,32,83. The great majority (86%) of comatose OHCA-VF 
patients were treated with TH in Study I.  The outcome results of Study I for VF patients 
treated with TH are comparable or even better than in previous studies13,131,136.  In RCTs 
good neurological outcome of OHCA patients have been reported to be between 49%-
55%13,14,17. In two large registry studies good neurological outcomes were found to be 44% 
in a study by Dumas and colleagues131 and 56% in a study by Nielsen and colleagues136 
respectively.  
A recent TTM-study randomized 950 OHCA patients to 36 hours temperature control 
either at 33°C or 36°C 17. In this trial no difference was found in neurological outcome or 
mortality between the groups treated at 33°C or at 36°C, and they reported mortalities of 
50% and 48% and good neurological outcomes (CPC 1-2) of 46% and 48% respectively. 
This well-known study changed the clinical practice later in many ICUs in Finland. The 
TTM study and Study I are not comparable because of different study settings, randomized 
vs. observational. But if comparing only the TH treated patients in Study I, good 
neurological outcomes (48%) are equal in both studies. The TTM study included all OHCA 
patients with presumed cardiac cause for arrest, and 20% had non-shockable rhythms, this 
compares with 22% of non-shockable patients from any cause for cardiac arrest in Study I. 
This difference may have had an influence on overall mortality and outcome results. 
Additionally in Study I, decisions to use TH was made by the clinicians, not randomization, 
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which may have had a beneficial effect on outcome due to the possible patient selection, 
despite the fact that reasons for withholding TH decisions were all based on clinical reasons.  
The findings in Study I do not support the previously reported association of better 
survival in larger hospitals or cardiac arrest centres compared to smaller hospitals96,232,238. 
One study reported some evidence that OHCA patients’ survival is better in ICUs treating 
more than 50 CA patients compared to ICUs with less than 20 CA admissions233. Great 
variation was found in Study I in the use of TH and number of treated patients, but patient 
outcomes did not associate with ICU size, number of treated patients or use of TH among 
participating ICUs. The variation in outcome and TH use between ICUs may be explained 
by variations in ICU and hospital resources across Finland together with variations in 
individual patients.  
 
6.5.2 Outcome of OHCA-non-VF-patients (I) 
The findings in Study I, are comparable to previous registry studies reporting outcomes of 
OHCA patients resuscitated from non-shockable initial rhythms, which has been shown to 
be significantly lower than patients with shockable initial rhythms129,131,136. These studies 
report good neurological outcomes (CPC 1-2) from 15% to 28%, respectively; the 
equivalent percentage was 17% in Study I. Some smaller studies have been reported good 
neurological outcomes127 of up to 50% and also an association between TH and improved 
outcome compared to patients treated without TH127,282. The results of Study I do not 
support the use of TH in OHCA-non-shockable patients, but this observational study 
cannot rule out any possible benefit. The lack of benefit of TH in this group of patients is in 
agreement with meta-analysis reporting TH association to reduced in-hospital mortality, but 
not to neurological outcome134. Two large registry studies, not included in the meta-analysis, 
also reported no significant association with neurological outcome and TH in patients 
resuscitated from non-shockable rhythm131,283. 
6.6 Strengths and limitations 
The main strength of this study is that all the individual studies were conducted on the same 
study population, which was prospectively collected and covered practically all OHCA 
patients treated in ICUs in Finland over one year. Due the observational nature of this 
multicentre study including 21 out of 22 ICUs, the study well represents the real life and 
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clinical practices in ICUs and its results are can be generalized to other populations. The 
majority of OHCA-VF-patients were treated with TH with comparable targets, which 
provided a fairly large and homogenous study cohort (III, IV). In addition, clinically relevant 
one-year neurological outcome was the primary endpoint for all studies.  Furthermore, a 
specialist in neurology, who was blinded to resuscitation variables or treatments in ICU, 
contacted the patients and used a structured phone interview to determine neurological 
outcome (I-IV). 
However, several limitations in these studies (I-IV) should be addressed. First the 
FINNRESUSCI study was an observational study and only associations can be shown, not 
causality. In Study I, even though the study population can be considered representative, 
only patients treated in the ICU were included in the study. Therefore, successfully 
resuscitated patients treated outside the ICUs, either with very good or very poor prognosis, 
are not included in the study population. Thus, the study population does not represent all 
OCHA patients in Finland, only those treated in the ICUs.  
An obvious strength of Study II is that all ABG values were collected and analysed for 
the first 24 hours in ICU care, but there are also some important limitations. First, ABG 
tensions were assumed to be constant between the ABG measurements and changes in 
minute ventilation or oxygen fraction were not taken into account at the time changes were 
made. Second, the first measured ABG values were used to represent admission values, 
because it was not possible to include ABG measurements prior to ICU admission in the 
analysis. Third, there was no individual control whether temperature correction was used or 
not in individual measurements of PaCO2 during TH, only the standard practice at each site 
(yes/no) for temperature correction was reported. 
In Studies III and IV the main limitation is that blood samples were not obtained for all 
patients, because written consent from a relative was required before the first blood samples 
were taken. However, in both studies patients with blood samples were comparable to 
whole FINNRESUSCI OHCA-VF study population in terms of baseline characteristics, 
resuscitation variables, treatment and outcome. Study populations in these studies (III and 
IV) were comparable, thus the studied populations are considered representative. Second, 
there is slight variation in ROSC and actual time delay for the first blood sampling, because 
admission samples were drawn between 0 to 6 hours from ICU admission and the time 
from ROSC to ICU admission varies. In Study IV only a relatively small proportion of the 
patients were examined by angiography, which may have given additional information of 
missed coronary occlusions and the need for revascularization.  
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6.7 Clinical implications 
The FINNRESUSCI study shows that the international guidelines for post resuscitation 
care were well implemented in clinical practice and even the newest guidelines were part of 
clinical practice in Finnish ICUs rapidly after their publication. The use of TH has still 
increased over the last years95 and nearly all OHCA-VF and also a significant portion of 
OHCA-non-VF patients are treated with TH as recommended in the latest international 
guidelines19. The guidelines also recommend avoiding hyperoxia and aiming at 94-98% 
oxygen saturation after CA19, which has also been well observed in Finnish clinical practice. 
The Finnish ICU society seems to follow guidelines and the challenges of their 
implementation is probably harder in some other countries284-286. Outcome for patients, 
especially TH treated OHCA-VF patients, was very good and it was not related to the size 
or location of the treating hospital. This finding indicates that the individuals in the Finnish 
population have the same possibilities for post resuscitation care no matter where they live. 
The FINNRESUSCI study results are included in a recent ILCOR advisory statement104, 
where ILCOR evaluated, and summarized the current evidence of Temperature 
Management After Cardiac Arrest by using the GRADE methodology. The 
FINNRESUSCI study results were also noted in the recent ERC guidelines for post-
resuscitation care19. The great majority of surviving patients were classified as having good 
neurological outcome (CPC 1-2) one-year after CA, which means that the numbers of 
surviving patients with poor neurologic performance is limited in Finland.  
Most treatment goals for CA patients in ICU have been extrapolated from other groups of 
patients with critical illness, like sepsis or TBI. The majority of CA patients remain 
comatose after ROSC and are treated with mechanical ventilation in ICU. Mild hypercapnia 
is associated with good neurological outcome after OHCA while hypocapnia has been 
suggested to be harmful. The results of Study II were noted in the latest international 
guidelines 19 and they recommended that practitioners should aim for normal values of O2 
and CO2 after CA. Ventilation strategy has a great influence on the partial pressures of O2 
and CO2 in comatose OHCA patients treated with TH and arterial blood pressures should 
be monitored carefully, because it seems that avoiding hypocapnia is more critical in OHCA 
patients than mild hypercapnia.  
 
None of the measured biomarkers S-100B, hs-TnT, hs-CRP or IL-6 provide significant 
additional assistance for clinicians in mortality or neurological outcome prediction, but 
admission IL-6 was associated with subsequent multiple organ dysfunctions.  Development 
of organ dysfunction after CA will worsen the patients’ outcome, so IL-6 may help 
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clinicians to prepare for the support of hemodynamics and tailor other treatment strategies 
to optimize the patients’ care.  
Hs-TnT is very capable of detecting acute coronary occlusion also after CA, so it could 
be a valuable tool, at least in theory, for selecting patients for early revascularisation. The 
latest guidelines for post resuscitation care recommend immediate coronary angiography 
and possible PCI for all OHCA patients of suspected cardiac origin with ST-elevation and 
consider early angiography in other patients without obvious non-cardiac cause for arrest19. 
However, the clinical importance of hs-TnT is considered limited in AMI and after OHCA 
according to the recent guidelines19,87. 
6.8 Future perspectives 
Despite the improved outcome in ICU treated OHCA patients, mortality is still high. In 
many countries, including Finland, ICU resources are limited. Therefore, ICU care should 
be focused on patients with a reasonable chance for a favourable outcome. Optimally, 
patients should return to the same state of health as before ICU care.  Early prognostication 
of outcome in CA population would help clinicians to make decisions in patient selection 
for ICU care or withdrawal of care in patients without a reasonable chance of recovery. So 
far, there is no reliable single factor that can be used to predict outcome, even though this 
area has been studied extensively. The main problem has been that a high specificity is 
needed to avoid withholding of ICU care to patients with a plausible possibility of survival. 
There is great variation among the CA patients, but the most powerful factors associated to 
outcome are related to pre-hospital scenarios, common to all patients. There are only robust 
data (yes/no) data available on some important factors (CPR provided by bystander, 
witnessed CA), or data are based on rough estimations (time delays to start of CPR, time of 
CA, ROSC). New available technologies will enable the collection of more precise data from 
actual resuscitation, quality of CPR, and “no-flow” and “low-flow” times. It is very probable 
that these factors have more influence on outcome than inaccurate binomial (yes/no) data. 
These data associations to outcome should be studied, and combining these data to other 
available factors associated to outcome could improve the precision of prognostication.  It 
should be possible to routinely collect these data in the future with the newest devices 
without any additional costs or interventions.  
Prediction of outcome after CA is very hard for individual patients in ICU care. The 
outcome for patients treated in ICUs has been improved significantly over the last years. 
Although implementation of therapeutic hypothermia in clinical practice has been the most 
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important single intervention that has improved outcome, intensive care has also developed. 
TH or TTM has improved the outcome of OHCA-VF patients, but the optimal 
temperature to use and the duration of temperature control are still unknown.  According to 
latest recommendations temperature should be maintained constant between 32°C and 
36°C for at least 24 hours for adults after OHCA with initial shockable rhythm19. It is 
possible that there is no single target temperature or time for all CA patients, but some 
patients might benefit from lower or a longer target temperature control, while some 
patients might get more side effects or do not any benefit from lower or longer temperature 
control. The most recent guidelines reflected by ERC and ESICM suggest that TTM should 
also be given to comatose OHCA patients resuscitated from non-shockable rhythm and 
IHCA patients19, despite evaluation of the literature by the GRADE methodology and the 
very low-quality of evidence104. These questions concerning the use of TTM should be 
clarified in appropriate study settings in further studies. 
Coronary artery disease and AMI are the most common reasons for cardiac arrest. Early or 
even immediate angiography combined with PCI (if required), is recommended for all CA 
patients with a presumed cardiac cause for arrest according to the latest guidelines. There 
are no randomized studies confirming the benefit of early coronary intervention for CA 
patients, thus these recommendations are based only on observational studies.  While 
hypoxic brain injury is the most common cause of death in CA patients, including VF 
patients, the main future focus should be on preventing or limiting the brain damage. It is 
possible that early coronary interventions may delay or even prevent other treatments 
essential for brain damage. Targeted temperature control, optimizing haemodynamics and 
ventilation are definitely more complex in a cardiac laboratory than in an ICU environment. 
It is possible to administer all these interventions with cardiac interventions, but it is 
demanding. Therefore, it is highly probable that invasive management is beneficial in 
OHCA patients with classic AMI manifestations, but this should be confirmed in further 
randomized studies. 
Another interesting area for preventing brain damage is drug therapy after cardiac arrest. 
Several drugs have been shown to have neuroprotective features, but so far none of these 
have been shown to increase neurological survival in cardiac arrest patients treated with or 
without temperature control. Inhaled xenon after cardiac arrest has been shown to be 
feasible in ICU circumstances and potentially has positive effects also for the heart287. 
OHCA patients treated with inhaled xenon had less white matter damage in magnetic 
resonance imaging (MRI) but no differences in mortality or neurological outcome have been 
found288. Xenon and other potential drugs should be studied in relevant study settings to 
confirm or rule out any possible benefits. Further studies in this area should focus on 
therapies, which could be combined easily in clinical practice.  
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7 CONCLUSIONS 
1. The incidence of adult OHCA-patients was 13/100 000/year in Finnish ICUs. The 
incidence of VF/VT patients was 7.4/100 000/year and PEA/ASY 5.6/100 
000/year. 
 
2. Therapeutic hypothermia was used in 62% of all comatose OHCA patients: in 86% 
of patients with VF/VT, and in 31% of patients PEA/ASY as their initial rhythm. 
One-year good neurological outcome of TH treated VF/VT patients (58%) is equal 
or higher than in most previous studies. The worse outcome of patients with 
PEA/ASY as an initial rhythm was in agreement with previous studies and TH did 
not associate with better neurological outcome in these patients.  
 
3. The prevalence of hyperoxia was rare in this study population and was not associated 
with one-year neurological outcome. Mild hypercapnia was associated with good one-
year neurological outcome and the outcome of patients with a combination of mild 
hypercapnia and mild hyperoxia was associated with improved one-year neurological 
outcome. 
 
4. High values of admission IL-6, but not hs-CRP or S-100B, are associated with 
subsequent organ dysfunction. High admission IL-6 and S-100B were associated with 
one-year poor neurological outcome, but only IL-6 predicted poor neurological 
outcome independently in OHCA-VF patients, as did age and time to ROSC.  
 
5. Admission hs-TnT was associated with one-year mortality and one-year poor 
neurological outcome but not hospital mortality. Hs-Tnt did not produce new 
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